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Although the thrombogenic nature of the surfaces of cardiovascular devices is an important 
aspect of blood biocompatibility, few studies have examined platelet deposition onto opaque 
materials used for these devices in real time. This is particularly true for the metallic surfaces 
used in current ventricular assist devices (VADs). Using hemoglobin depleted red blood cells 
(RBC ghosts) and long working distance optics to visualize platelet deposition, we sought to 
perform such an evaluation. A titanium alloy (Ti6Al4V) and 5 alternative opaque materials were 
examined.  Ti6Al4V had significantly increased platelet deposition relative to the majority of 
alternative materials.  
Blood flow patterns are of particular concern for devices such as blood pumps where 
shearing forces can be high, volumes are relatively large, and the flow fields can be complex.   
However, few studies have examined the effect of geometric irregularities on thrombus 
formation on clinically relevant opaque materials under flow. The second objective of this report 
was to quantify human platelet deposition onto titanium alloys, as well as positive and negative 
control surfaces, in the region of crevices (~50-150 µm in width) that might be encountered in 
many VADs. The results revealed that the largest crevice size was the least thrombogenic. At the 
higher shear rate, the most deposition occurred in the medium size crevice.  
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A third challenge in assessing the hemocompatibility of a blood-wetted device is 
understanding the functional relationship between shear stress, biochemical agonists, and 
artificial surfaces. The final objective of this report was to investigate the effect of sub-threshold 
concentrations of ADP in conjunction with flow on platelet deposition onto clinically relevant 
opaque materials. To achieve this aim, a membrane-based agonist delivery system was designed 
to evenly introduce specific concentrations of agonists into a flowing blood analog. The results 
showed that that the addition of a sub-threshold level of ADP to the system resulted in nearly a 
2.5 fold increase in deposition on the titanium surface. The data generated from this report could 
be used to improve the accuracy of a predictive model of thrombotic deposition in VADs. 
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1.0  INTRODUCTION 
1.1 SIGNIFICANCE 
Blood-contacting medical devices are often associated with thrombotic, and thromboembolic 
events that result in morbidity and mortality, which ultimately impedes the broader adoption of 
these technologies.[1-5]  The propensity for platelet adhesion, activation and thrombus formation 
are key considerations in the design and selection of materials for blood-wetted devices. The 
majority of cardiovascular devices, such as vascular grafts, stents, and heart valves, are 
susceptible to thrombosis and thromboembolic events. In these devices platelets are subjected to 
areas of varying flow patterns, high wall shear stress, and exposure to a multitude of biochemical 
agonists (ADP, Ca++, thrombin, thromboxane A2, etc.).[6]+ 
 Continuous flow ventricular assist devices (VADs) present particular blood 
biocompatibility challenges due to their complex blood flow pathways, supra-physiological shear 
rates, large blood contacting surface areas, and extended implant periods in patients with 
advanced cardiovascular disease. In the United States it is estimated that there are over 100,000 
patients with end stage heart failure that could benefit from a heart transplant. However due to 
the limited organs available, only around 2200 transplants are likely to be performed in 2015.[7] 
VADs were originally designed to provide circulatory support to end stage heart failure patients 
while awaiting a heart transplant (bridge to transplant (BTT)) by mimicking the biphasic flow of 
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the native heart.[8, 9] However, the power and volume displacement necessary for pulsatile flow 
required these devices to be large, limiting their use in smaller heart failure patients. The 
introduction of rotary and centrifugal pumps decreased the size and power requirements of 
VADs, increasing the patient population eligible to receive the device. These pumps utilized a 
single rotating impeller to support the patient with continuous perfusion of blood, increasing 
their mechanical durability, allowing the device to be implanted for extended periods of time. 
These devices may also improve destination therapy (DT), a possibility for patients who do not 
qualify for heart transplantation.[10] This report focuses on continuous flow VADs. Despite 
improvement in VAD technology, the threat of thromboembolic events and pump thrombosis 
continues to be a major concern for these patients.[1, 2, 11, 12]   
1.2 THROMBOSIS AND BLEEDING COMPLICATIONS ASSOCIATED WITH 
CONTINOUS FLOW VENTRICULAR ASSIST DEVICES 
As more centers started implanting a variety of VADs, the need for a standardized definition of 
thromboembolic events and a method for analyzing these events in patients became apparent. To 
address this need, the Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) was developed. INTERMACS is a national database sponsored by the National 
Heart, Lung and Blood Institute in partnership with the U.S Food and Drug Administration 
(FDA) and the Centers for Medicare and Medical Services.[1, 13, 14] This database provides a 
method for acquiring important VAD implant information, including adverse events and 
mortality rates. It also provides a standard definition for major adverse events like bleeding, 
neurological dysfunctions and pump thrombosis.[15]  
 3 
 In an INTERMACS report published in 2014, continuous flow VAD patients had a one 
year survival rate of 81%.[1] This is substantially higher than end stage heart failure patients who 
are not supported by a device who only have a 1 year survival rate of around 50%.[16] 
Continuous flow VAD patients also experienced a 89%, 83%, and 81% freedom from major 
neurological events at 1, 2, and 3 years of device support (N=5436).[13] The rate of neurological 
dysfunction within this patient population was 1.83 (events/ 100 patient months in the first 12 
months after implantation). Bleeding and pump malfunction events were also reported, with a 
rate of 9.45 and 1.60 respectively (events/ 100 patient months in the first 12 months after 
implantation).[13] The overall survival for continous flow VAD patients continues to be high 
with a 1 and 2 year survival rate of 80% and 70% respectively.[1] However their actual freedom 
from any major adverse event (infection, bleeding, device malfunction, stroke, or death) is only 
48% after 3 months and only 14% after 3 years [13] Reperesentative images of thrombos in 
continuous flow VADs are shown in Figure 1.[17] 
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Figure 1. Representative images of thrombosis in a continuous flow VAD (HeartMate II; Thoratec Corp, 
Pleasanton, CA, USA). A) Thrombosis in the bend relief and B) the pump. From Cheng et al. [15] 
 
Currently, one of the most widely used continuous flow VADs is the Thoratec HeartMate 
II (Thoratec Corp, Pleasanton, CA, USA) axial flow pump.[18, 19] Several studies have reported 
on adverse events experienced by patients who are supported by this device. Data reported in 
2007 from the HeartMate II bridge to transplant (BTT) clinical trial found that 6% of the VAD 
recipients experienced ischemic strokes, 2% hemorrhagic stroke, 2% pump thrombosis requiring 
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pump replacement, and 84% of patients suffered a bleeding event, with 41% requiring re-
operation (133 patients).[20]  In 2009, a report by Pagani et al. published results gathered from 
the continuation of the HeartMate II BTT trial. This report revealed that the incidence of 
bleeding was decreased to 79%, with 26% requiring re-operation (1.67 and 0.45 events/patient 
year, respectively). The incidence of ischemic and hemorrhagic stroke remained essentially the 
same at 5% and 3% respectively (0.09 and 0.05 events/patient year respectively). 1% of the VAD 
patients had primary device thrombosis requiring surgical intervention (0.04 events/patient year; 
281 patients).[21] The HeartMate II was approved by the FDA for BTT indications in 2008. A 
report on the post-approval trial by Starling et al. revealed the incidence of bleeding continued to 
be high, with 44% of HeartMate II patients experiencing a bleeding event (1.44 events/patient 
year). Furthermore, 4.7% of patients experienced an embolic stroke event (0.06 events/patient 
year) and 1.2 percent of patients suffered hemorrhagic stroke (0.01, 169 patients).[22]  
The HeartMate II was approved for destination therapy (DT) indication in 2010 and it is 
currently the only continuous flow device approved for this purpose.[18] A 2009 report on the 
HeartMate II DT clinical trial revealed that 81% of the patients experienced a bleeding event 
(1.66 events/patient year) with another 30% requiring re-operation for bleeding (0.23 
events/patient year). It was also reported that 18% of patients suffered a stroke, 8% of which 
were thromboembolic in nature. Another 4% had pump thrombosis (134 patients).[23] Since this 
study, the popularity of using VADs for DT has increased. The most recent INTERMACS report 
stated that nearly half of the continuous flow VADs implanted from 2011-2013 were for DT 
indications (41%). This report did show that the 2-year survival of patients supported for DT was 
10% lower than that of patients supported for BTT (61% and 78% respectively). However, the 2-
year survival rate of patients supported by the Heartmate II for DT is substantially higher than 
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the 2 year survival rate for the pulsatile VADs patient and patients receiving optimal medical 
management as reported in the Randomized Evaluation of Mechanical Assistance for the 
Treatment of Congestive Heart Failure (REMACH) Trial (23% and 8% respectively).[9] 
Another continuous flow VAD that is widely used in clinics is the HeartWare HVAD 
(HeartWare Inc, Framingham, MA, USA). The HVAD is a centrifugal flow pump with 
magnetically and hydrodynamically levitated impeller. This impeller-levitating technology 
eliminates the need for mechanical bearings, improving the fluid dynamic design of the VAD. 
However, the HVAD and other 3rd generation pumps are still associated with hemocompatibility 
issues.[18, 24]  In 2011, Strueber et al. reported that 12% of patients supported by the HVAD for 
BTT experienced stroke, 4% of which were ischemic, 30% had incidences of bleeding, with 20% 
needing re-operation, and another 8% needed a device replacement due to left heart embolus 
(N=50 patients).[25] The U.S. clinical trial for the use of the HVAD for BTT indicates that 
14.8% of patients experienced bleeding events that necessitated re-operation, 12.7% experienced 
gastrointestinal bleeds, 15.3% suffered stroke with 7.5% being ischemic and 4.2% needed pump 
exchange due to expected or confirmed pump thrombosis. (N=332 patients).[26] 
Due to the relative success of continuous flow VAD therapy, clinicians have considered 
implanting the devices in less sick patients.[1] The INTERMACS profile for advanced heart 
failure was developed to categorize the health status of heart failure patients, where a higher 
level indicates a more stable patient (Table 1).[15] INTERMACS data show that VAD patients 
whose INTERMACS profile level is greater than 2 at implantation have a 5%-8% increase in 1 
year survival rate compared to those who are characterized as INTERMACS profile level 2 or 
lower.[9, 13] In a single center study of patients who received the HVAD for BTT, the outcomes 
for patients who were characterized as either INTERMACS level 1/level 2 or INTERMACS 
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level 3/level 4 at the time of implantation were compared.  Patients who were INTERMACS 
level 3/level 4 had improved survival rates compared to the less stable patients (30 day survival 
rate of 90% and 50% respectively). The more stable patients also had a greater freedom from 
stroke at 81% compared to 48% with the INTERMACS level1/level 2 patients (N=50 
patients).[27] Despite these results, the risk of thrombotic and thromboembolic events remain 
high. In the same study they found that 22% of patients suffered ischemic stroke, 4% suffered 
hemorrhagic stroke, and 26% of patients experienced bleeding that required re-operation.[27] 
Another recent single center study reported by Wu et al. in 2013 found that 6.81% of patients 
suffered from a neurological dysfunction.[28] The substantial adverse events experienced by 
VAD patients are deterrents for implanting the device in healthier patients. This is particularly 
true because patients who receive optimal medical treatment (OMT) for heart failure tend to 
experience reduced incidence of these events. A study reported by Rogers et al. found that 11% 
of OMT patients treated for a comparable length of time as VAD implantation experienced 
stroke while 0% experienced bleeding (N=18 patients).[29] Similarly, Rose et al. found 
neurological dysfunction at a rate of 0.09 events/patient year and no bleeding events (61 
patients).[30] Furthermore, Witt et al. performed a meta-analysis that found only 5% of heart 
failure patients experienced ischemic stroke within the first 5 years of diagnosis.[31] Therefore, 
these hematological adverse events associated with VADs deter the broader acceptance of this 
technology for use in less-sick patients. 
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Table 1. INTERMACS Profiles of Advanced Heart Failure. Manual of Operations and Procedures, Version 4.0. 
Available at https://wwwuabedu/medicine/intermacs/mop-4-0 [15] 
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 A 2013 report by Starling et al. showed a concerning and sudden increase in HeartMate 
II pump thrombosis across three major implant centers: the Cleveland Clinic, Washington 
University Barnes-Jewish Hospital, and Duke University. The data showed that before 2011 only 
2.2% of patients experienced pump thrombosis within 3 months of support, while this number 
increased four-fold to 8.4% of patients implanted from 2011 to 2013 (837 patients, Figure 
2).[32] It is not known why this increase has occurred. Since the device has been approved for 
destination therapy, the device has most likely been implanted in sicker patients (patients who do 
not qualify for transplantation). It is also possible that pump thrombosis was originally 
underreported because it is difficult to diagnose without explanting the device. Pump thrombosis 
particularly concerning because the 1 year patient survival rate decreases with each device 
replacement at 80% with the original device, to 65% after the second implant, and only 50% 
after the third implantation.[1] This and similar reports that have shown an unexpected increase 
in thromboembolic events in patients who have received HeartMate II and HVAD [32, 33], has 
lead the FDA to issue a safety communication stating the potential risk associated with the use of 
these devices its greater than originally reported at the time of regulatory approval.[34] Thus, the 
timeliness of a more thorough investigation into the potential triggers for thrombotic deposition 
in VADs is clear and this challenge extends to several other blood-contacting medical devices. 
 10 
 
Figure 2. Increase in confirmed HeartMate II pump thrombosis at three active implanting institutions after 
March 2011. From Starling et al. [32] 
 
DeVore et al. reported that the HeartMate II destination therapy trial determined that the 
cost for continuous flow VADs is $190,148 per quality-adjusted life year (QALY). This does 
not, however, meet the cost-effectiveness metric for the U.S.[35] Puehler et al. reported a similar 
statistic stating that the mean cost for continuous flow support is $193,812 per QALY.[9]  One 
method to improve the cost effectiveness of continuous flow VADs is to develop more 
biocompatible VADs. In order to achieve this goal, further investigation into how fluid 
dynamics, material selection, and hemostatic condition of the patient affect the potential for 
device thrombosis is needed. 
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1.3 VIRCHOW’S TRIAD APPLIED TO VENTRICULAR ASSIST DEVICES 
Virchow’s triad is a summation of factors that cause the development of thrombosis. According 
to this triad, these three components are abnormalities in the vessel wall, abnormalities in the 
blood constitution, and abnormalities in the blood flow. Although Virchow first published his 
work in 1856, the concept is still applicable today and can be translated to explain the factors 
involved in device thrombosis.[36] When applying Virchow’s triad to cardiovascular devices 
such as VADs, the three factors that affect thrombosis development are: the reactivity of the 
biomaterial, the hemostatic state of the patient’s blood, and the blood flow.[37, 38]  As stated 
earlier, continuous flow VADs have complex blood flow pathways, supra-physiological shear 
rates, large blood contacting surface areas, and are often implanted in patients with pro-
thrombotic conditions. Therefore, to fully investigate the thrombotic and thromboembolic issues 
associated with continuous flow VADs all three factors of the triad must be analyzed as well as 
their functional relationship with each other. 
1.3.1 Biomaterial 
When blood comes into contact with an artificial material, proteins quickly adhere to the surface. 
Initially the surface becomes covered in proteins that are in the highest concentration within the 
plasma or smaller proteins that are easily diffused towards the surface. However, over time these 
proteins are replaced by larger less diffusible proteins that have a higher affinity for the surface. 
This is known as the Vroman effect.[39] Blood interaction within the VAD occurs between the 
absorbed proteins and the patient’s blood. Platelets adhere to blood-contacting surfaces through 
receptors that bind with specific absorbed plasma proteins. The most common platelet adhesion 
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receptors are glycoprotein IIb/IIIa (GP αIIbβ3) that binds to absorbed fibronectin, fibrinogen, and 
von Willebrand factor and glycoprotein Ib (GP Ib).  At higher shear rates GP Ib is the dominant 
receptor whereas at lower shear rates binding is dependent on GP IIb/IIa. [39, 40] The surface 
chemistry of the biomaterial dictates the conformation of the absorbed proteins. Consequently, it 
is the surface chemistry that dictates whether the appropriate binding sites will be exposed to the 
blood in order to initiate platelet adhesion.[41]  
A substantial portion of biomaterials research has been devoted to developing methods to 
reduce the thrombogenicity of these devices through their design and surface manipulation.[6, 
10, 40, 44, 45] Numerous reports have focused on developing inert, nonfouling materials to 
prevent platelet adhesion and subsequent thrombus formation. For example, the anticoagulant 
heparin has been immobilized through covalent bonding, ionic bonding, and physical 
adsorption.[6, 10, 44, 45] To reduce platelet deposition onto common metallic biomaterials, 
coatings such as diamond like carbon (DLC) and 2-methacryloyloxyethyl phosphorylcholine 
(MPC) polymers have been investigated.[10, 40, 44] Although a wide array of approaches have 
been investigated to reduce material thrombogenicity, thrombosis complications remain of 
clinical significance for many devices. Thus surfaces with improved biocompatibility, as well as 
methods to quantify such improvements, remain of interest to the cardiovascular device 
community. 
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Continuous flow VAD manufacturers often use a polished titanium alloy (TiAl6V4) as 
the blood contacting surface due to its desirable mechanical properties, resistance to corrosion 
and tolerable blood compatibility.[42] However, in vitro studies have shown that this alloy 
exhibited elevated acute thrombogenicity compared to other coated surfaces (e.g., polyethylene 
glycol and diamond-like carbon coatings) or related alloys (Ti6Al7Nb).[6, 43-45] Representative 
images of the thrombogenicity of Ti6Al4V compared to other materials and surface coatings are 
displayed in Figures 3 and 4.[43, 46] 
 
 
Figure 3. Representative digitized images of platelet adhesion on a) low-temperature isotropic carbon (LTIC) b) 
diamond-like carbon (DLC) c) Ti6Al4V (Ti). From  Schaub et al. [43] 
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Figure 4. Scanning electron micrographs of platelets adhered to A) Ti6Al4V B) trimethoxy silane modified Ti6Al4V 
(Ti-TMSi) C) Silanated zwitterionic phosphorylcholine modified Ti6Al4V (Ti-PCSi) D) Salanated sulfobetaine 
modified Ti6Al4V (Ti-SBSi). Platelet deposition is reduced when the titanium alloy is modified by PCSi and SBSi. 
From Ye et al. [46] 
1.3.2 Blood Flow 
Platelet deposition is dependent upon the transport of platelets from the bulk phase to the 
surface.[39, 40] At higher shear regions (> 30 dyne/cm2), platelet aggregation is mediated by 
platelets binding to vWF through the GP IB receptor. Continuous flow VADS contain regions of 
pathologically high shear stresses (>100 dyne/cm2). Studies have shown that these high shear 
stresses can activate platelets and lead to thrombosis development in VADs.[47, 48] 
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The blood flow path plays a major role in the formation of thrombi. Areas of flow 
separation, recirculation, and stagnation lead to increased platelet adhesion and thrombus 
formation.[49-52] In vivo, thrombosis is often found in regions of irregular geometries such as 
bifurcations, stenosis and aneurism, which are characterized by hazardous flow fields.[49] These 
patterns occur when flowing blood is unable to follow the rapid changes in the contour of the 
flow path created by the irregular geometries, causing flow separation, stagnation and 
recirculation.[52] Similar to these pathological conditions, areas of flow separation, recirculation, 
and stagnation are produced in several blood-wetted devices, such as VADs, heart valves, stents, 
and vascular grafts, because of sudden changes in the shape of the blood flow path. [52-56] Yang 
et al. utilized fluorescent particles to visualize the flow patterns in the HeartMate II in vitro. The 
report revealed that when the pump is run at typical clinical conditions (3.0-4.0 L/min at 9000 
rpm), areas of erratic flow are found near the bearings before and after the stator (Figure 5).[57] 
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Figure 5. High-speed flow visualization of flow within the HeartMate II pump utilizing flow fluorescent particles. 
Pump was run at clinically relevant speeds. Areas of erratic flow found near the bearings and after the stator. From 
Yang et al. [57] 
 
Geometric irregularities, such as steps and crevices, within the flow path of continuous 
flow VADs are known to serve as nidi for thrombus formation.[49] Because VADs are a 
complex assembly of multiple parts, the creation of internal steps and crevices is generally 
unavoidable. These features commonly occur at the sites where multiple components are mated. 
Manufacturers make a great effort to reduce the presence of these features within their devices 
through precise machining and polishing. Despite precautions, it is impossible to completely 
eliminate these unwanted topographies. This design challenge is illustrated in a figure (Figure 6) 
taken from Zhao et al.[49] Figure 6A shows the complexity of a rotary VAD design. An 
exaggerated view of the geometric irregularities that are created in the flow path of the pump due 
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to the combination of components is depicted in Figure 6C. These features are often the site of 
pump thrombosis because they cause flow separation, stagnation, and recirculation (Figure 6D). 
For example, Figure 6B shows that a ring thrombus formed at the transition between the metal 
barb and the polymer cannula of a pediatric VAD. A method for determining the effect of these 
erratic flow patterns on thrombus formation would be a useful tool in improving the design of 
VADs.  
 
 
Figure 6. The design challenge of continuous flow ventricular assist devices. (a) A section of rotary blood pump; (b) 
ring thrombus formed at the transition between metal barb and polymer cannula of a pediatric continuous flow 
blood pump; (c) exaggerated magnified view of the irregular geometries located at the seams of blood-wetted 
devices; (d) well-known flow separation downstream of a backward step. From Zhao et al. [49] 
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1.3.3 Blood Constitution 
Heart failure patients often have abnormal coagulation that increases their risk of stroke and 
thrombotic events prior to VAD implantation. This hypercoagulable state may be caused by 
many factors. Reduced myocardial contractility leads to low cardiac output and abnormal blood 
flow that can initiate coagulation.[58] Patients with heart failure often have dysfunctional 
endothelium, which can no longer act as an anticoagulant barrier. This dysfunction reduces the 
release of endothelium-derived nitric oxide (NO). NO acts to inhibit the platelet adhesion and 
activation in vivo, therefore a reduction of this factor increases the risk of thrombosis.[59, 60]  
Another event that could lead to a hypercoagulable state in continuous flow VAD 
patients is infection. Infection occurs at a rate of 9.96 events/ 100 patient months in the first 12 
months post-implant, and can elevate plasma levels of inflammatory cytokines such as tumor 
necrosis factor alpha and interleukin-1 (IL-1) that are known to initiate coagulation.[1, 58, 59] 
Investigating how pre-activation of platelets affects the formation thrombosis on biomaterials 
under flow could increase the understanding of device-centered thrombosis and lead to the 
development of more biocompatible VADs. 
Due to the thrombogenic nature of continuous flow VADs, patients are on continuous 
anticoagulation and antiplatelet medications. Heparin is used preoperatively and during the initial 
recovery from implantation to get the patient’s partial thromboplastin time (PTT) between 40-60 
sec.[61] Heparin is a highly sulfated glycosaminoglycan that binds to and increases the activity 
of Antithrombin III, an enzyme inhibiter that inactivates thrombin. [62] Heparin is eventually 
replaced with warfarin and aspirin to get an international internalized ratio (INR) of 2.0-3.0.[61, 
63-67]  Warfarin is a vitamin K inhibitor, preventing the synthesis of several biologically active 
forms of calcium dependent clotting factors (Factor II, VII, IX and X).[68] Aspirin acts as an 
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anti-platelet medication by inhibiting cyclooxygenase (COX-1), which is necessary for platelet 
activation through the arachidonic acid pathway.[69] Clopidogral (Plavix), an anti-platelet 
medication that reduces platelet activation through inhibiting the P2Y12 (ADP) receptor, is also 
sometimes utilized.[58] This therapy is a delicate balance between preventing thrombosis and 
causing bleeding. An investigation of the effect of anticoagulant medications on thrombus 
formation onto biomaterials under clinically relevant flow conditions may be utilized to develop 
improved therapies. 
1.4 PREDICTIVE MODELS OF DEVICE THROMBOSIS 
Trial and error is commonly used by device manufacturers to reduce the risk of biocompatibility 
complications. This method is time-consuming and expensive, with often unpredictable 
outcomes. With advancements in computer technology and mathematical modeling, several 
mathematical and computer models have been developed to predict platelet deposition and 
thrombus formation in blood wetted devices.[70-75] Such a model would reduce the time and 
cost of designing and producing safe, effective blood-wetted devices and could be used to 
determine thrombogenic areas of devices prior to implantation. However the accuracy of the 
current models is limited by the lack of experimental data characterization of platelet deposition 
onto opaque surfaces under clinically relevant flow conditions. 
For example, in 1992 Fogelson et al. developed a set of convection-diffusion-reaction 
(CDR) equations to simulate the transport of thrombin and other platelet agonists in a growing 
thrombus. This model incorporated platelet activation kinetics, wherein resting platelets are 
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considered activated if exposed to threshold concentrations of agonist.[76] This model was 
further developed by Sorensen et al.  by integrating several previously disjointed components 
such as the inclusion of both active and resting platelets, and various platelet agonists, platelet 
activation kinetics, agonist production and consumption, conversion of thrombin and 
antithrombin III (ATIII) into thrombin-antithrombin (TAT), platelet-surface reaction kinetics, 
and  thrombin inhibition by heparin and direct inhibitors.[77, 78] Several investigators utilized 
the Sorensen model to simulate platelet deposition in saccular aneurysms [79], expanding 
channels [80], tube flow [81], and corrugated channels [82] In 2010 Leiderman et al refined the 
model to consider coagulation biochemistry, platelet activation, platelet deposition and the effect 
of the thrombus formation on the flow field. Although this model provides an excellent 
representation of thrombus growth due to exposed subendothelium, it limits platelet activation 
and coagulation events to a thin reaction zone, just above a small vascular injury, which is not 
applicable to blood-wetted devices with complex geometries and flow patterns.[83] 
Experimental data that quantifies the effect of clinically-relevant biomaterials and flow patterns 
on thrombus formation may be used to calibrate and validate a predictive model of thrombosis in 
VADs. 
1.5 SUMMARY OF INTRODUCTION 
The incidence of thrombosis, bleeding, and neurologic dysfunction experienced by patients 
supported by continuous flow VADs continues to limit the cost-effectiveness and clinical 
acceptance of the technology. Biomaterial-centered thrombosis and its subsequent 
thromboembolism remain of high relevance as designers seek to improve the blood 
 21 
biocompatibility of future generation VADs and other cardiovascular devices. The development 
of an experimental method to characterize platelet deposition onto opaque surfaces under 
clinically relevant flow conditions would be a useful tool in generating data to validate 
computation models of thrombosis in blood-wetted devices, enabling the design of more 
hemocompatible VADs. 
1.6 OBJECTIVES 
As discussed in the sections above, continuous flow VADs present several blood 
biocompatibility challenges making it difficult to predict thrombosis within these devices. 
Evaluating the time dependent, platelet adhesion onto the blood-contacting surfaces of 
cardiovascular devices, under clinically relevant flow conditions, could be a useful tool in 
designing more hemocompatible VADs. Despite the large volume of research dedicated to 
characterizing and improving the blood biocompatibility of biomaterials, few studies have been 
performed to assess time dependent platelet adhesion onto opaque materials. Furthermore, the 
majority of materials used for cardiovascular devices are opaque, making it difficult to image 
microscopic platelet deposition onto these surfaces in real time. The aim of this research is to 
characterize real time platelet deposition onto opaque surfaces under clinically relevant flow 
conditions, in order to generate data to advance the accuracy and utility of predictive models of 
thrombosis in blood-wetted cardiovascular devices. This was accomplished through in vitro 
studies composed of the following objectives: 
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1.6.1 Objective # 1: Real time visualization and characterization of platelet deposition 
under flow onto clinically relevant opaque surfaces 
Continuous flow VAD manufacturers often use a polished titanium alloy (TiAl6V4) as the 
blood-contacting surface of their devices. However, in vitro studies have shown TiAl6V4 to have 
elevated acute thrombogenicity compared to other candidate materials or coatings. Due to 
erythrocyte opacity it has been difficult to develop a method for assessing real time platelet 
deposition onto TiAl6V4 and other alternative opaque materials using whole blood.  Employing 
the use of optically clear hemoglobin depleted red blood cells (RBC ghosts), a parallel plate flow 
chamber, and long working distance optics we sought to perform such an evaluation. 
1.6.2 Objective # 2: Visualization and Analysis of Biomaterial-centered Thrombus 
Formation within a Defined Crevice under Flow 
Although the majority of VAD manufacturers attempt to make the blood contacting surfaces of 
their devices as smooth as possible, all VADs are composed of combined components that 
inevitably generate crevices and steps along the flow path. These regions produce areas of 
recirculating flow and are often the nidus of thrombus formation in these devices. A custom 
designed parallel plate chamber containing crevices of defined dimensions was employed to 
investigate the effect of crevice size on platelet adhesion to clinically relevant opaque materials. 
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1.6.3 Objective # 3: Characterizing the effect of sub-threshold concentrations of ADP on 
platelet deposition onto clinically relevant opaque materials 
Another challenge in assessing the hemocompatibility of a blood-wetted device is understanding 
the functional relationship between shear stress, biochemical agonists, and artificial surfaces. To 
perform such an analysis, a membrane based agonist delivery system was design to evenly 
introduce specific concentrations of agonist into the blood analog prior to the blood contacting 
the test material. Using this method, the affect of sub-threshold concentrations of ADP on 
platelet deposition onto clinically relevant opaque materials, under flow, was characterized. 
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2.0  REAL TIME VISUALIZATION AND CHARACTERIZATION OF PLATELET 
DEPOSITION UNDER FLOW ONTO CLINICALLY RELEVANT OPAQUE 
SURFACES 
(Note: A majority of this chapter was previously published as: Jamiolkowski MA, Woolley JR, 
Kameneva MV, Antaki JF, Wagner WR. Real time visualization and characterization of platelet 
deposition under flow onto clinically relevant opaque surfaces. Journal of biomedical materials 
research Part A. 2015;103:1303-11.) 
2.1  INTRODUCTON 
The manufacturers of the Heartmate-II and other continuous flow VADs currently use a polished 
titanium alloy (Ti6Al4V) as the blood contacting surface due to its desirable mechanical 
properties, resistance to corrosion, and tolerable blood compatibility.[42] However, in vitro 
studies have shown that this alloy exhibited elevated acute thrombogenicity compared to other 
coated surfaces (e.g. polyethylene glycol and diamond-like coatings) or related alloys 
(Ti6Al7Nb).[43-45, 84] This study was therefore conducted to perform a systematic side-by-side 
comparison of six candidate biomaterials currently being considered for application in 
continuous-flow blood pumps. However, since these materials are opaque, traditional methods 
for real time visualization of platelet deposition, such as fluorescent microscopy utilizing whole 
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blood, are not readily applicable. The present study demonstrates a method to overcome this 
limitation through the use of a blood analogue containing transparent, hemoglobin depleted red 
blood cells (RBC ghosts) combined with fluorescently-labeled platelets. The experimental 
preparation consisted of a parallel plate flow chamber with epifluorescence microscopy having a 
long working-distance objective. This preparation permitted real-time observation of deposition 
and embolization to identify promising alternatives to Ti6Al4V to improve the overall blood 
compatibility of the device, reducing reliance on anticoagulation and anti-platelet agents. 
2.2 MATERIALS AND METHODS 
2.2.1  Platelet Collection and Fluorescent Labeling   
Fresh whole blood was collected after informed consent from 27 healthy donors (13 male, 14 
female), who had refrained from taking any platelet altering medications 14 days prior to 
collection, with a mean age of 35±12 years in accordance with Institutional Review Board 
guidelines. Platelet-rich-plasma (PRP) was collected by centrifuging citrated blood (5 mL 
Vacutainer tubes, [0.105M] citrate, BD, Franklin Lakes, NJ, USA) at 250xg for 15 min. Platelets 
(2.7 ± 0.30 × 108 per mL) were fluorescently labeled by the addition of quinacrine 
dihydrochloride (0.5 μM final concentration, Sigma-Aldrich, St. Louis, MO, USA) to the PRP. 
Quinacrine dihydrochloride was chosen because studies have shown that platelet function is not 
affected when a final concentration < 20 μM is used.[85, 86] 
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2.2.2 RBC Ghost Preparation and Characterization 
Packed RBCs (type O-, Valley Biomedical Products & Services, Inc., Winchester, VA, USA) 
were converted into RBC ghosts through the modification of established protocols.[87-90]  
Briefly, the RBCs were rinsed and centrifuged (2000×g, 15 min) three times with phosphate 
buffered saline without Ca2+ or Mg2+ (PBS, VWR International LLC., Radnor, PA, USA) and 
then suspended in PBS at a 50% hematocrit. While incubated between 0-6oC, 1 mL of RBC 
suspension was added to every 9 mL of a lysing solution composed of 4mM MgSO4, 5X 
concentrated PBS (25 mL per L distilled water), and acetic acid (Sigma-Aldrich, 80 μL per L of 
distilled water) in distilled water with a final osmolality of 40 mOsm and pH of 5.0-5.2. After 5 
min incubation, osmolality and pH were increased to physiologic norms (300 mOsm and 7.8, 
respectively) by the addition of 0.3 mL of 5X concentrated PBS and 2µL of 1M Tris buffer 
(Thermo Fisher Scientific Inc., Pittsburgh, PA, USA) per mL of cell suspension and stored at 0-6 
degrees C for 8 hrs. The cells were then resealed by incubation at 37°C for 1 hr. The suspension 
was centrifuged at 25400xg for 30 min and the supernatant was discarded. The cells were 
washed 3 times with PBS (25400×g for 30 min) and stored in PBS with 100 mg/L gentamicin 
(Thermo Fisher Scientific). The resulting RBC ghosts were observed to be translucent. The 
donor PRP was utilized within 6 hr after being drawn to minimize platelet activation. Therefore 
RBC ghosts were prepared prior to the blood draw and added to the donor PRP. Blood type O- 
RBCs were used to create RBC ghosts cells to allow mixing with any donor PRP blood type. The 
RBC ghosts were stored up to 2 wk at 4-6°C and a final hematocrit of  ≥ 95%. These cells were 
utilized in the perfusion experiments within this time. 
 Prior to RBC ghost creation, an aliquot of native RBCs was set aside for comparative 
rheological testing in the Kameneva laboratory. The viscosity of RBC ghosts in human plasma 
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was measured using a cone and plate viscometer (Brookfield Digital Rheometer, Model DV-III, 
Brookfield Engineering Laboratories, Inc., Stoughton, MA, USA) and compared to native RBCs 
at the same hematocrit. The elongation of RBC ghosts and native RBCs at various wall shear 
rates was measured using an optical rheology system (CSS-450, Linkam Scientific Instruments 
Ltd., Tadworth, Surrey, UK) and analyzed using ImageJ (NIH). The elongation index was 
calculated as (L−W)/(L+W) where L and W are the major and minor axes of the ellipse 
representing elongated RBC, respectively.  
2.2.3 Test Materials 
Ti6Al4V and 5 alternative materials or coatings were analyzed: Ti6Al4V (Supra Alloys Inc., 
Camarillo, CA, USA), a modified 2-methacryloyloxyethyl phosphorylcholine polymer coated 
Ti6Al4V (MPC-Ti6Al4V), silicon carbide (SiC; CoorsTek, Inc., Golden, CO, USA) alumina 
(Al2O3; CoorsTek), yttria partially stabilized zirconia (YZTP; CoorsTek), and Zirconia 
Toughened Alumina (ZTA; CoorsTek). All the materials had a mirror polish finish. MPC-
TI6AL4V was prepared in the authors’ laboratory using previously reported protocols.[46] The 
materials evaluated were selected for their physical characteristics, which were generally 
compatible with use as blood contacting materials in a continuous flow VAD. A contact angle 
goniometer (VCA optima, AST Product Inc., Billerica, MA) was used to measure the contact 
angle of 1 μL of distilled water at room temperature on each surface. All samples were cleaned 
with Simple Green® (Thermo Fisher Scientific Inc.) and Tergazyme® (Alconox, Inc., White 
Plains, NY, USA) and then sonicated three times with distilled water prior to testing using a 
protocol based on the cleaning methods utilized for continuous flow VADs undergoing 
preclinical testing.[91] 
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2.2.4 Parallel Plate Flow Chamber 
The parallel plate flow chamber design was similar to that described by Kent et al.[92] The top 
plate was clear acrylic with angled nylon inflow and outflow luer connectors, and the bottom 
plate was the interchangeable test material. A simple clamping mechanism held the plates 
together, with a silicone gasket outlining the channel width and length (5 x 8 mm). Aluminum 
shim stock was placed between the plates to provide a precisely defined channel height of 0.076 
mm (Figure 7A-7B). The flow within this chamber was assumed to be one-dimensional laminar 
parallel plate flow (Reynolds numbers between 0.1 and 0.4).[43, 92] 
2.2.5 Blood Analogue Perfusion and Image Acquisition 
The experimental flow path is presented in Figure 7C. All non-test surfaces were passivated by 
incubation with 1% bovine serum albumin (BSA, microbiological grade powder; MP 
Biomedicals, LLC, Solon, OH, USA) in PBS for 20 min prior to perfusion. To verify 
passivation, platelet deposition onto the acrylic top plate was qualitatively assessed after the 
perfusion experiments. Few to no adherent platelets were found. Quinacrine dihydrochloride - 
labeled PRP was mixed with RBC ghosts to produce an end hematocrit of 25% and a final 
platelet concentration of 2.0 ± 0.2 × 108 platelets/mL. This suspension was collected into a 20 
mL polystyrene syringe (BD Biosciences) and pulled through the parallel plate flow chamber by 
a syringe pump (Harvard Apparatus, Holliston, Massachusetts, USA) for 5 min at flow rates of 
0.118 and 0.295 mL/min (wall shear rates of 400 sec-1 and 1000 sec,-1 respectively). These wall 
shear rates were chosen to represent a low (400 sec-1) and high (1000 sec-1) physiological rate. 
Continuous flow VADs produce a wide range of wall shear rates within the pumps, including 
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supra-physiological wall shear rates of  >25000 sec-1 (shear stress  > 100 N/m2 ).[93-95] 
However, the wall shear rates represented in this study are characteristic of those produced 
within the inlet and outlet regions and along the outer wall of centrifugal VADs (e.g. the 
clinically utilized HeartWare) [93, 94] and near the inlet in a region called the inducer in axial 
flow VADs (e.g. the clinically utilized HeartMate II).[95] 
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Figure 7. Parallel plate flow chamber and experimental set up. A) The circular metallic piece and rectangle were 
secured around the flow chamber with screws. B) The flow path was formed from a silicon gasket. Thin aluminum 
shim stock can be seen along the length of either side of the silicone gasket to ensure a precise chamber height. C) 
The blood analogue was perfused through the chamber and across the sample for 5 min. Images were acquired, in 
real time, 4mm from the inlet by a CCD camera. The transparent blood analogue and long working distance 
objective allowed for real time visualization of adherent fluorescent platelets through the flow path onto the opaque 
test surface. 
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Platelet adhesion was visualized within a 200x200 micron region of interest, located 4 
mm downstream from the inlet connector, in real time, using an inverted epifluorescence 
microscope (Olympus IX FLA, Olympus Corporation, Shinjuku, Tokyo, Japan) with a 40x super 
long working distance objective (PlanFL, phase contrast, working distance 6.5 mm - 8.3 mm, 
numerical aperture 0.55, and maximum acceptable coverslip thicknesses of 2.6 mm; Olympus 
Corporation) and a 103W HBO short arc mercury lamp light source (OSRAM GmbH,Munich, 
Germany). Images were acquired every 0.4 sec beginning at one min after the start of perfusion 
using a CCD camera (PCO-TECH Inc., Romulus, Michigan, USA).  
Images were analyzed by thresholding the intensity, subjectively to eliminate spurious 
artifacts (See Figure 8A and 8B.). The surface coverage (in percent) of deposited platelets was 
computed using a custom written program in MatLab (MathWorks, Inc., Natick, MA, USA). To 
visually determine the accuracy of the analysis the outline of the original image was overlaid 
onto the original image (Figure 8C). 
 
 
Figure 8. Image analysis to quantify the percent platelet surface coverage. A) Original fluorescent image of 
platelets adhered to SiC after 5 min of perfusion, B) binary image rendered by the MatLab program, C) original 
fluorescent image overlaid with the outline of the binary image. Scale bar = 40 μm. 
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2.2.6 Scanning Electron Microscopy 
Following perfusion, samples were gently rinsed with PBS and incubated with glutaraldehyde 
(2.5% in PBS; Sigma-Aldrich) for 10 min. Next, the materials were washed 3 times with PBS 
and dehydrated in consecutive stages of increasing ethanol (Sigma-Aldrich) concentrations. The 
samples were then chemically dried with hexamethyldisilazane (Thermo Fisher). Finally, the 
samples were coated with gold-palladium (Hummer VI Sputtering System, TechnicsWest, Inc., 
San Jose, California, USA) and scanning electron micrographs (SEMs) were obtained (images 
obtained using scanning electron microscope model JSM6330F, JEOL, Tokyo, Japan). 
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2.2.7 Flow Cytometry 
Bulk phase activation of the platelets was measured by flow cytometry using previously 
described methods.[96] Briefly, blood was sampled from the exit port of the parallel plate 
chamber at two points in time: immediately after the sample initially crossed the test surface 
(determined visually) and also after 5 min perfusion. Aliquots of these samples were incubated in 
buffer solution (Tyrode’s solution with 1% BSA, Electron Microscopy Science, Hatfield, PA, 
USA) with fluorescein isothiocyanate – conjugated mouse anti–human CD42b (CD42b, clone 
LG.3A10; AbD Serotec, Raleigh, NC, USA ) and either recombinant phycoerythrin–conjugated 
(RPE) mouse anti-human CD62P or RPE-conjugated isotype- matched control antibody (CD62P 
and Mouse IgG1, clones Psel.KO.2.5 and W3/25, respectively; both from AbDSerotec ) in the 
dark for 20 min. The cells were washed with Tyrode’s solution with 1% BSA and 0.106 M 
sodium citrate dehydrate (Thermo Fisher), centrifuged, and the pellet isolated. The cells were re-
suspended in 1% paraformaldehyde (Sigma-Aldrich) and stored at 4° C (<24 hr) until analyzed. 
CD42b+ events (>5000) were collected on a 3-color FACScan (BD Biosciences) and analyzed 
with WINList software (Verity Software House, Topsham, ME).  
2.2.8 Statistical Analyses 
All data are presented as mean ± standard error of the mean. Data were analyzed by two-way, 
repeated measures ANOVA with specific post-hoc (eliminated space after hypen) testing using 
the Bonferroni correction. SPSS v20 (IBM Corp, Armonk, NY) was used for all statistical 
analyses. 
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2.3 RESULTS 
2.3.1 RBC Ghost Rheology 
To verify that flow behavior of RBC ghosts is similar to that of native RBCs, the rheological 
properties of RBC ghost suspensions were examined by comparing their viscosity as a function 
of shear rate to that of native RBCs used for the ghost preparation. Figure 9A depicts the 
viscosity response of native and ghost RBCs in plasma over a range of shear rates. No difference 
between the two curves was found (Figure 9A, P=0.61). Similarly, there was no difference 
found in deformability of the original RBCs and their ghosts (Figure 9B) and in their calculated 
elongation indices (Figure 9C; P = 0.41). Additionally, no significant difference in bulk phase 
platelet activation was detected between PRP and PRP mixed with RBC ghosts (8.7 ± 0.9% and 
7.3 ± 0.9%, respectively; P=0.13, N=5). 
 
 
Figure 9. A) Comparing the viscosity of native and ghost RBCs in human plasma at a matched hematocrit of 27%. 
B) Mixture of native and ghost RBCs subjected to a wall shear rate of 1100 sec-1. Red and blue arrows indicate a 
native and ghost RBC respectively. Scale bar = 40 μm. C) Deformability of native and ghost RBCs. 
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2.3.2 Acute Platelet Adhesion on Test Surfaces 
Representative fluorescent images of platelet adhesion onto the 6 opaque test surfaces after 5 min 
of perfusion at wall shear rates of 400 and 1000 sec-1 are shown in Figure 10. At the lower wall 
shear rate of 400 sec-1, Ti6Al4V had 6.0% ± 2.0% (n=7) platelet deposition after 60 sec of 
perfusion, which continued to increase throughout the test resulting in platelet surface area 
coverage of 11.2 ± 1.6% (Figure 11). Similarly, SiC had 5.5% ± 1.2% (n=7) at 60 sec of 
perfusion which increased to 15.6 ± 2.2% in 5 min.  Platelet adhesion onto Ti6Al4V and SiC 
increased significantly with time and were not different from each other (P<0.05). In contrast, 
Al2O3, YZTP, ZTA, and MPC-TI6Al4V all had significantly lower platelet adhesion (P<0.005) 
than the previous two surfaces, with  average end platelet surface coverage of 3.3 ± 0.9%, 2.5 ± 
1.1%, 1.3 ± 0.3%, and 1.2 ± 0.5%, respectively (Figure 11). 
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Figure 10. Representative fluorescent images of platelets adhered to A) Ti6Al4V, B) SiC, C) Al2O3, D) YZTP, E) 
ZTA, and F) MPC-TI6AL4V after 5 min of perfusion. Scale bar = 40 μm. 
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Figure 11. Acute platelet adhesion on test materials perfused at a wall shear rate of 400 sec-1.  Images were 
acquired at 4mm distance from the inlet of the parallel plate flow chamber. 
 
At the higher wall shear rate of 1000 sec-1, all of the test materials had significantly less 
platelet adhesion than Ti6Al4V (P<0.001) (Figure 12). After 5 min perfusion, Ti6Al4V had 
platelet surface coverage of 4.8 ± 1.0%. In contrast, Al2O3, SiC, YZTP, ZTA, and MPC-
TI6Al4V had average end platelet surface coverage of 1.2 ± 0.3%, 0.66 ± 0.35%, 0.60 ± 0.17%, 
0.32 ± 0.13%, and 0.63 ± 0.23%, respectively.  
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Figure 12. Acute platelet adhesion on test materials perfused at a wall shear rate of 1000 sec-1.  Images were 
acquired 4mm from the inlet of the parallel plate flow chamber.  
39 
Representative accelerated videos of real-time perfusion and platelets adhesion to all 
six surfaces, at wall shear rates of 400 or 1000 sec-1 are available in the 
supplemental material of this report (Video 2.1-2.12). Although all materials had 
visible platelet deposition present during the experiments, the most pronounced thrombi 
formations were clearly observed with the Ti6Al4V samples at high and low wall 
shear rates and SiC samples at low wall shear rates. The thrombi grew in elliptical 
patterns, with the long axis aligned in the direction of flow. Embolization of fragments 
and entire thrombi were observed sporadically with the Ti6Al4V, SiC, Al2O3, and 
YZTP samples. Examination of the length of the flow path following perfusion indicated 
that platelets reacted uniformly with the test materials and were not diffusion-limited 
by the rapid depletion of platelets onto the surface at the inlet of the chamber.[77] 
2.3.3 Wall Shear Rate Effect on Platelet Adhesion 
Curves comparing platelet adhesion to each of the six test surfaces at the two wall shear rates are 
presented in the supplemental material (Figure 13). Increasing the wall shear rate from 400 
to 1000 sec-1 produced a trend of decreased platelet adhesion to the test surfaces. This trend 
was significant for all of the surfaces, except MPC-Ti6Al4V (P<0.05). The largest change in 
platelet adhesion between wall shear rates occurred with SiC, in which a 95 ± 2% decrease in 
platelet surface coverage was observed at t = 5 min at the higher perfusion rate.  
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Figure 13. Comparison of the effect of wall shear rate on acute platelet adhesion. Note Ti6Al4V and SiC are scaled 
differently than the other materials. P<0.01 between shear rates for all materials except MPC-Ti6Al4V. 
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2.3.4 Surface Contact Angles, Scanning Electron Microscopy and Flow Cytometry 
Water contact angles of the materials measured prior to use were as follows; Ti6Al4V: 55.3 ± 
3.1°, SiC:  72.14 ± 3.6°, Al2O3: 69.2 ± 2.7°, YZTP: 31.3 ± 2.0°, ZTA: 42.0 ± 2.1°, and MPC-
Ti6AL4V:  20.6 ± 2.1°. Scanning electron micrographs of platelet deposition following blood 
analogue perfusion revealed similar adhesion patterns on the material surfaces as shown in the 
fluorescent images (Figure 14). Similar to the fluorescent images, the scanning electron 
micrographs revealed oval thrombi aligned in the direction of flow on the Ti6Al4V at both wall 
shear rates and on SiC at a wall shear rate of 400 sec-1. Also, these micrographs verify that there 
is substantially less platelet deposition on the four other test surfaces. From the flow cytometry 
data, there was no difference found between materials or over the course of the perfusions in 
bulk phase platelet activation or circulating platelet-platelet microaggregate formation (P > 0.25). 
The average percent of activated platelets and microaggregates across all of the materials at both 
time points were 8.0 ± 2.1% and 1.2 ± 0.3% respectively 
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Figure 14. Representative scanning electron micrographs of platelets adhered to A) Ti6Al4V, B) SiC, C) Al2O3, D) 
YZTP, E) ZTA, and F) MPC-TI6AL4V after 5 min of perfusion. Scale bar = 40 μm. 
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2.4 DISCUSSION 
Characterization of the in vitro thrombogenicity of surfaces is an important step in developing 
and selecting new materials for use in blood-wetted devices. Previous methods  examining acute 
platelet deposition have utilized end-point analysis [97, 98] required the material to be 
transparent [99] or have used PRP instead of blood to perfuse over the surfaces.[100] The use of 
RBC ghosts mixed with PRP allows for a more physiologically relevant analysis of platelet 
deposition. Native RBCs have been shown to be involved in the transport of platelets to the 
vessel wall.[88] When blood flows through the microvessels the RBCs migrate towards the 
center of the vessels, crowding the platelets outward and increasing their concentration at the 
vessel wall.[49, 88] This phenomenon has also been observed with in vitro flow systems, where 
the increased platelet gradient near the test surfaces enhances platelet-surface interactions and 
increases the likelihood of platelet adhesion.[49, 101] A recent computational model of platelet 
adhesion in shear flow suggests that platelet adhesion is dependent upon near-wall collisions 
with RBCs.[102]  
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The axial migration of RBCs that promotes platelet transport away from the center of 
vessels is also dependent on the unique abilities of RBCs to deform and aggregate.[103, 104] 
The combination of aggregation and the deformability of RBCs are also responsible for the 
shear-thinning characteristics of whole blood.[105]  Because the ghost RBCs produced in this 
study had an identical viscosity curve and deformability as native red blood cells they are 
expected to produce the same transport phenomena. Therefore, optically clear RBC ghosts were 
deemed acceptable substitutes for native RBCs in order to maintain the increased platelet 
concentration near the chamber walls while producing a transparent test fluid.  
A parallel plate microfluidic device was chosen for this study because it provided one-
dimensional, laminar flow and a defined wall shear rate.[43, 92] Szarvas et al. [106] found the 
parallel plate flow chamber to be superior to the cone and plate viscometer as the latter reduced 
surface-specific platelet deposition and experienced an increased reduction in single platelets 
with time. Other studies have utilized commercially available rotating disk or modified cone and 
plate viscometer systems to examine platelet adhesion to artificial surfaces with a wall shear 
stress gradient along the diameter of the disk or plate.[107-110] However, real-time videos of 
platelet deposition on opaque surfaces using whole blood with these systems have not yet been 
described. Uchida et al. used a cone and plate viscometer to show that time dependent platelet 
adhesion could be reduced by coating commercially pure titanium with apatite, and apatite 
composites. However, images were only acquired every 5 min for a total of 15 min and PRP was 
utilized instead of whole blood.[108] Furukawa et al. modified a cone and plate viscometer with 
transparent quartz glass which allowed for real time imaging of epifluorescent platelet deposition 
onto clear and opaque materials. However, PRP was still used as the perfusion fluid.[110]  
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Schaub et al. previously presented a method for visualization of time-dependent platelet 
deposition on opaque surfaces.[43] In that report platelet deposition was measured on opaque 
metallic and polymeric materials at discrete time points by introducing into the fluid path a fiber 
optic bundle coupled to an epifluorescent microscope. However, this technique allowed for only 
brief periodic visualization of platelet adhesion with a limited field of view (100 μm diameter).  
Additionally, each time the fiber optic bundle was inserted into the chamber it altered the fluid 
dynamics of the system, potentially influencing subsequent observations. The methods described 
in this report avoid all these limitations by providing an increased field of view, improved image 
quality, and no disturbance to the flow field.  
Variations in the extent and nature of protein adsorption, particularly fibrinogen, would 
be expected to be related to the variation in platelet adhesion observed between materials. Ye et 
al. previously incubated Ti6Al4V and MPC-Ti6Al4V in buffer solution containing ovine 
fibrinogen and quantified surface protein adsorption.[46] It was found that MPC-Ti6Al4V had 
significantly less fibrinogen adsorption than the unmodified titanium alloy, which could explain 
the marked reductions in platelet adhesion observed in this study.[46] While it has been 
demonstrated that fibrinogen from plasma dominates as the blood adsorbate driving platelet 
adhesion on artificial surfaces [111], a key factor is the conformational state of the adsorbed 
fibrinogen and not necessarily the total amount of adsorbed protein.[112] The employment of 
monoclonal antibodies specific for platelet binding sites on fibrinogen would be a means to 
investigate whether the trends in platelet adhesion observed in this study for the various opaque 
surfaces could be directly related back to fibrinogen adsorption and orientation on the 
surface.[112] 
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In this study, all materials exhibited an inverse relationship between wall shear rate and 
area of platelet coverage. Previous studies that investigated the effect of shear rate on platelet 
adhesion onto highly thrombogenic surfaces, such as type I collagen or tissue factor, showed that 
platelet deposition increased directly with shear rate.[113, 114] This may simply be due to higher 
shear rates being associated with greater platelet transport to these surfaces, which are highly 
platelet reactive.[77, 78] For the surfaces used in this study, the reduced platelet deposition at 
higher wall shear rates could be explained by shorter periods of interaction between near-wall 
platelets and surface-bound ligands or greater drag forces on platelets forming transient surface 
bonds.[77, 78] The results suggest that reducing device regions under a low wall shear rate may 
aid in lowering device thrombogenicity. Of particular note was the 23-fold drop in platelet 
coverage observed with the SiC samples at the end of the 5 min perfusion. While the results 
indicate less than 1% surface area coverage at the 1000 sec-1 wall shear rate, the videos show 
transient thrombotic deposition that embolizes quickly before larger thrombi can form. This is a 
qualitative observation that was unable to be analyzed quantitatively. While the discrete time 
point results suggest that SiC is less thrombogenic than Ti6Al4V at this wall shear rate, the 
accompanying real-time video suggests that SiC has material properties that encourage 
embolization and may present a clinical risk should the phenomenon occur in vivo and allow the 
shedding of emboli large enough to trigger tissue ischemia. Hoffman et al. reported similar 
material properties with hydrogel coatings where blood-contacting materials implanted in 
animals would lack obvious deposition onto the test surfaces at the time of explant, but where the 
animals had infarcts in tissue beds distal to the hydrogels.[115] 
Trial and error approaches to materials selection and flow path design may be used by 
device manufacturers in an effort to reduce thrombogenicity complications.  Such methods are 
 47 
time-consuming and expensive, with often unpredictable outcomes. Computational models have 
been developed to reduce the time and cost of designing and producing safe, effective blood-
wetted devices.[70, 72, 73, 116, 117] Flamm et al. [117] performed a multiscale simulation of 
platelet deposition onto collagen under flow. The images produced from this simulation were 
visually similar to the real-time images of platelet deposition onto Ti6Al4V in the current report, 
suggesting that this computational model might also be applicable to synthetic biomaterials. The 
data collected form this study could be used to advance the accuracy and utility of such 
predictive models of thrombosis in blood-wetted cardiovascular devices. 
2.5 LIMITATIONS 
An obvious limitation to this study is its acute, in vitro nature. Test materials were subjected to 
blood analogue perfusion for five min, whereas the tested materials would be implanted for 
much longer periods of time. However, when screening an array of alternative materials for in 
vivo testing, those forming large thrombi or experiencing substantial embolization acutely might 
be eliminated in favor of less reactive alternatives.  A possible alternative to using a single-pass 
experiment would be utilizing a recirculating flow loop. This would allow for longer perfusion 
times and increase individual platelet interactions with the material surface through multiple 
passes. However, the blood would also contact larger areas of non-test surfaces, introducing 
artifact in the system.  
Another potential limitation in this study is the use of a dilute suspension of red blood 
cells (25% hematocrit). Although this is lower than the average hematocrit for healthy 
individuals, it is not atypical for patients implanted with VADs.[118] Sodium citrate was used to 
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limit the platelet activation caused by the blood draw. This may have reduced bulk phase platelet 
activation and microaggregate formation during the experiment. Heparin could have been used to 
mimic the anticoagulants given to VAD patients; however, studies have shown that the in vitro 
use of heparin as an anticoagulant can result in a greater incidence of spontaneous platelet 
aggregation and activation when compared to sodium citrate.[119, 120]  
When RBC ghosts are prepared, the majority of their contents are released and replaced 
with a saline solution. Thus RBC ghosts contain markedly less adenosine diphosphate (ADP) 
when compared to native RBCs, raising concerns that they may not be a suitable model because 
this platelet agonist could not be released as in the native RBCs. However, because the flow 
produced in the flow chamber is steady laminar flow and the wall shear rates to which the RBCs 
are exposed are physiological, there should be limited hemolysis or shear-induced ADP release. 
A final limitation of note is that thrombus growth in the vertical direction and total 
platelet deposition was not quantified in these experiments. While earlier work has shown that 
the overall fluorescence intensity of the microscopic field of view might be used as a correlate of 
platelet deposition, this was not possible with the current system.[121] High background 
fluorescence from free quinacrine dihydrochloride in the clear perfusate was a confounding 
factor here, as was the lack of opaque RBCs to quench this free fluorophore. The temporal 
measurements of platelet adhesion should thus be considered in the context of the video data, 
which demonstrate that the platelet adhesion was reflective of the formation of distinct thrombi. 
The observation that the thrombi grow in elliptical patterns in the downstream direction is in 
agreement with similar studies investigating mural thrombus formation.[122] These thrombi 
would presumably also grow in the vertical direction as later arriving platelets preferred to join 
existing thrombi rather than adhere to patches of the surface where platelets were not adhering. 
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2.6 CONCLUSIONS 
Mixing of RBC ghosts with fluorescently-labeled platelets creates an effective blood analogue 
with which the acute thrombogenicity of opaque blood-contacting materials can be assessed. 
This method was used to evaluate several materials under consideration for utilization in blood-
contacting medical devices, such as VADs. The reduced platelet deposition at elevated wall 
shear rate that was observed in this study suggests that the blood biocompatibility of VADs 
might be improved by minimizing the areas of low shear blood contact. Furthermore, this 
technique revealed that MPC-TI6AL4V and ZTA have improved thromboresistance when 
compared to Ti6Al4V and, thus, may be alternatives for consideration in future VAD designs.  
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3.0  VISUALIZATION AND ANALYSIS OF BIOMATERIAL-CENTERED 
THROMBUS FORMATION WITHIN A DEFINED CREVICE UNDER FLOW 
3.1 INTRODUCTON 
Geometric irregularities, such as steps and crevices, within the flow path of continuous flow 
VADs serve as a nidus for thrombus formation.[49] Manufacturers make a great effort to reduce 
the presence of such features within their devices prior to implantation through precise 
machining and polishing. However, VADs are comprised of multiple parts that serve to create 
the blood contacting surfaces. So, the introduction of internal steps and crevices is unavoidable, 
at some level. Also, there is the possibility that surface imperfections can be introduced during 
the operation of some devices, for instance when a non-fixed VAD impeller collides with a 
housing surface and creates a scratch.[123] 
Understanding how surface irregularities affect the development of thrombotic deposition 
on clinically relevant biomaterials would provide a useful tool for improving the blood flow path 
design and materials selection process for VADs and other blood-contacting medical devices. 
Such data could be used directly or in the development of mathematical models that seek to 
predict thrombotic deposition risk for a given biomaterial/geometry combination. To date, the 
use of flow visualization technologies such as particle image velocimetry (PIV) have become 
routine in blood pump design, as has the early evaluation of candidate biomaterials by acute 
blood contact under well-defined flow conditions or simple mixing.[6] There have been a limited 
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number of in vitro studies that have examined real-time platelet deposition onto biomaterials in 
regions of disturbed flow.[72, 124] These reports did not evaluate geometries associated with 
device joints or surface imperfections and generally evaluated disturbances on a much larger 
scale. Further, these reports did not evaluate the opaque metallic materials used in the rotary 
blood pumps in common clinical use today. The objective of this report was to quantify human 
platelet deposition onto Ti6Al4V alloys, as well as positive and negative control surfaces, in the 
region of crevices (~50-150 µm in width) that might be encountered in many VADs or other 
cardiovascular devices. To achieve this, reconstituted fresh human blood with hemoglobin-
depleted red blood cells (RBC ghosts, to achieve optical clarity while maintaining relevant 
rheology), long working optics, and a custom designed parallel plate flow chamber were 
employed. 
3.2 MATERIALS AND METHODS 
3.2.1 Blood analog preparation  
Fresh whole blood was collected after informed consent from 12 healthy donors (7 male, 5 
female), who had refrained from taking any platelet altering medications 14 days prior to 
collection, with a mean age of 27 ± 6 years in accordance with Institutional Review Board 
guidelines. Platelet rich plasma (PRP) was collected by centrifuging citrated blood (collected 
into 5 mL Vacutainer tubes, [0.105M] citrate, BD, Franklin Lakes, NJ, USA) at 250xg for 15 
min. Platelets were fluorescently labeled by the addition of quinacrine dihydrochloride (0.5 μM 
final concentration, Sigma-Aldrich, St. Louis, MO, USA) to the PRP.  Packed RBCs (type O-, 
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Valley Biomedical Products & Services, Inc., Winchester, VA, USA) were utilized to create 
RBC ghosts through an established protocol.[125] The blood analog used as the perfusate was 
made by mixing the fluorescently labeled PRP with the RBC ghosts to produce a final hematocrit 
of 25% and a final platelet concentration of 2.7 ± 0.30 × 108 per mL. 
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3.2.2 Parallel plate flow chamber 
A custom parallel plate chamber was designed for this study. Flow channels containing crevices 
of defined dimensions were prepared from polydimethylsiloxane (PDMS) using a photo-etched 
silicon mold. The perfusion apparatus is shown in Figure 15. The main flow channel is 3 x 8 mm 
and includes one of three crevice dimensions (53 ± 7 x 122 ± 4 µm2 (n=7), 90 ± 12 x 122 ± 4 
µm2 (N=7), or 137 ± 10 x 122 ± 4 µm2 (N=80).  Silicon tubing (Silicon® Med-X Tubing; United 
States Plastic Corporation, Lima, Ohio, USA) was connected to the PDMS channel as inlet and 
outlet connectors. A titanium alloy sample (Ti6Al4V; LaunchPoint Technologies Inc., Goleta, 
CA, USA) acted as the bottom plate of the chamber. Ti6Al4V was selected for study since it is 
employed by several current and experimental VADs for blood-contacting surfaces.[84] Platelet 
deposition on rat tail, type I collagen coated glass coverslips (Neuvitro Corporation, Vancouver, 
WA, USA; N=5) and a TiAl6V4 surface that had been modified with methacryloyloxyethyl 
phosphorylcholine polymer (MPC-Ti6Al4V, N=5) were employed as positive and negative 
thrombogenic control surfaces respectively. The control surfaces were employed in perfusions 
utilizing the 90 µm wide crevice. MPC-TI6AL4V was prepared in the authors’ laboratory using 
previously reported protocols.[46] A simple clamping mechanism held the plates together and 
acrylic shim stock was placed between the plates to provide a precisely defined channel height of 
0.1 mm (Figure 15B). The flow within this chamber was assumed to be one-dimensional laminar 
parallel plate flow (Reynolds numbers between 0.1 and 0.4).[43, 92] 
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Figure 15. Experimental Setup. A) Schematic of the flow path utilized in this study with magnified view of the 
rectangular crevice. The arrow indicates the direction of flow B) Photograph of parallel plate chamber with 
magnified view of the rectangular crevice. C) Schematic of the experimental layout. D) Photograph of the actual 
experimental layout. 
3.2.3 Blood analog perfusion and image acquisition 
All non-test surfaces were passivated by incubation with 1% bovine serum albumin (BSA, 
microbiological grade powder; MP Biomedicals, LLC, Solon, OH, USA) in PBS for 20 min prior 
to perfusion. The whole blood analog was collected into a 20 mL polystyrene syringe (BD 
Biosciences) and pushed through the parallel plate flow chamber by syringe pump (Harvard 
Apparatus, Holliston, Massachusetts, USA) for 10 min at flow rates of 0.125 and 0.310 mL/min 
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(wall shear rates of 400 sec-1 and 1000 sec-1 respectively at the center of the channel). Platelet 
deposition was visualized within the crevices, in real time, using an inverted epifluorescence 
microscope (Olympus IX FLA, Olympus Corporation, Shinjuku, Tokyo, Japan) with a 40x super 
long working distance objective (PlanFL, phase contrast, working distance 6.5 mm - 8.3 mm, 
numerical aperture 0.55; Olympus Corporation) and a 103W HBO short arc mercury lamp light 
source (OSRAM GmbH, Munich, Germany). Images were acquired every 0.4 sec beginning at 
one min after the start of perfusion using a CCD camera (PCO-TECH Inc., Romulus, Michigan, 
USA).  
3.2.4 Fluorescent image analysis 
The percent of the surface covered by deposited platelets was computed through established 
protocols.[125] Images were also analyzed to determine the probability of platelets adhering to a 
specific region within the crevice and the average intensity of the adherent platelets utilizing 
ImageJ (NIH, Bethesda, MD, USA) and custom designed MatLab (MathWorks, Inc., Natick, 
MA, USA) programs. Briefly, to calculate the probability of platelet adhesion, images were 
converted from grayscale to binary. All pixels that were brighter than a predetermined threshold 
were rendered white (platelets) and given a value of 1, whereas all pixels below that threshold 
were rendered black and given the value of 0. At discrete time points, the corresponding values 
of the pixels from each test were summed and divided by the total number of experiments. 
Intensity color maps were generated by averaging the intensity of the deposited platelets at 
discrete time points.  
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3.2.5 Statistical analysis 
All data are presented as mean ± standard error of the mean. Data were analyzed by two-way, 
repeated measures ANOVA with specific post- hoc testing using the Bonferroni correction. 
SPSS v23 (IBM Corp, Armonk, NY) was used for all statistical analyses. 
3.3 RESULTS 
3.3.1 Probability of acute platelet adhesion 
The probability maps generated from the acquired fluorescent images of platelet deposition 
within the various crevice sizes on TI6Al4V are displayed in Figures 16 and 17. In all color map 
images, flow in the main channel was directed downward. When the blood analog was perfused 
at a wall shear rate of 400 sec-1, the region with the greatest probability of adhesion for all three 
crevice sizes occurred at the distal corner, nearest the main channel (Figure 16). This region 
increased in area over time. After 10 min of perfusion a region on the proximal corner, nearest 
the main channel of the 53 µm and 90 µm crevices also contained a high probability of platelet 
adhesion (>75%). Adhesion was least likely to occur in the largest crevice (137 µm). 
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Figure 16. Color maps depicting the local probability of platelet deposition within each crevice size, over time, at a 
perfusion rate of 125 µL/min and a wall shear rate of 400 sec-1. The direction of flow is down for the main channel, 
outside of the crevice.  
 
Increasing the wall shear rate to 1000 sec-1 resulted in the greatest probability of platelet 
adhesion again being located at the distal corner, nearest the main channel for the 53 and 90 µm 
crevices (Figure 17). However, this region did decrease in size with the increase in wall shear 
rate. Within the 137 µm crevice, the platelets mainly adhered along the distal wall with a 
maximum probability of adhesion <50%. 
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Figure 17. Color maps depicting the probability of platelets depositing within each crevice size, over time, at a 
perfusion rate of 310 uL/min and a wall shear rate of 1000 sec-1. The direction of flow is down for the main channel, 
outside of the crevice. 
 
When comparing different surfaces at both wall shear rates, the greatest adhesion 
occurred on the type I collagen with regions having a high probability (>75%) of platelet 
adhesion being located at both the distal and proximal corner, nearest the main channel. Similar 
to Ti6Al4V, these regions of platelet adhesion increased with time. MPC-Ti6Al4V was the least 
thrombogenic with a maximum probability of platelet adhesion <30% in the limited region 
where this occurred (Figures 18 and 19). Upon increasing the wall shear rate from 400 to 1000 
sec-1, platelets were more likely to adhere along the distal wall of MPC-Ti6Al4V instead of at the 
distal corner. 
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The fluorescent images were further analyzed to determine the percent of the analyzed 
blood contacting surface covered by adherent platelets over time (Figure 20).  At the 400 sec-1 
wall shear rate, the 53 µm and 90 µm crevice had significantly greater adhesion compared to the 
137 µm crevice, with a platelet surface coverage of 19.9 ± 1.6% , 16.7 ± 2.9% and 10.4 ± 1.4% 
respectively. (P=0.01, Figure 20A). Comparing the materials, collagen had the greatest surface 
coverage with 23.1 ± 3.2% after 10 min of perfusion and MPC-Ti6Al4V had the least amount of 
adherent platelets with a maximum surface coverage of 1.1 ± 0.2 % ( P<0.01, Figure 20B). 
 
 
Figure 18. Color maps depicting the probability of platelets depositing on each material, over time, at a perfusion 
rate of 125 µL/min and a wall shear rate of 400 sec-1.  Crevice size of 90 ± 12 µm. The direction of flow is down for 
the main channel, outside of the crevice.  
 
 60 
 
Figure 19. Color maps depicting the probability of platelets depositing on each material, over time, at a perfusion 
rate of 310 µL/min and a wall shear rate of 1000 sec-1.  Crevice size of 90 ± 12 µm. The direction of flow is down for 
the main channel, outside of the crevice.  
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Figure 20. The percent of the surface covered by deposited platelets. A) The effect of crevice size on platelet surface 
coverage at a wall shear rate of 400 sec-1. B) The effect of material on platelet surface coverage at a wall shear rate 
of 400 sec-1. Crevice size of 90 ± 12 µm. C) The effect of crevice size on platelet surface coverage at a wall shear 
rate of 1000 sec-1. D) The effect of material on platelet surface coverage at a wall shear rate of 1000 sec-1. Crevice 
size of 90 ± 12 µm.  
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Increasing the wall shear rate to 1000 sec-1 significantly decreased the percent platelet 
coverage within the 53 µm, 90 µm and the 137 µm (P<0.01, Figure 21). However, the increase 
in wall shear rate did not result in a significant change in adhesion for the collagen and MPC-
Ti6Al4V samples. At the higher wall shear rate, the 137 µm crevice had least amount of platelet 
adhesion compared to the other crevice sizes at 1.7 ± 1.1% (P<0.01). The 90 µm crevice had 
significantly greater platelet coverage at 8.7 ± 0.5% compared to the 137 µm and 53 µm crevices 
(1.7 ± 1.1% and 6.6 ± 0.6% respectively, P<0.01). 
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Figure 21. Effect of wall shear rate on platelet surface coverage. A) 137 ± 10 µm. B) 90 ± 12 µm. C) 53 ± 7 µm. D) 
Collagen. E) MPC-Ti6Al4V. 
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3.3.2 Average intensity of deposited platelets 
 Color maps depicting the average fluorescence intensity from deposited platelets on Ti6Al4V 
(Figure 22 and Figure 23) and the control materials (Figure 24 and Figure 25) within the 
crevices were generated to provide a 3-dimensional approximation of thrombus formation, 
assuming that stacked platelets led to higher local fluorescence intensity.[121] The greatest 
platelet deposition occurred on the collagen surface and the 90 µm crevice often became 
completely occluded after 10 min of perfusion. The images were thus normalized to the greatest 
average intensity exhibited by those collagen control surfaces that were completely occluded. At 
both wall shear rates the region of high platelet deposition (intensity >15; maximum intensity 
=25) occurred at the distal corner of the crevice nearest the main channel in the 53 and 90 µm 
crevices. However these regions of high platelet deposition were smaller in size when the blood 
analog was perfused at a higher wall shear rate. Platelets were least likely to deposit in the 137 
µm crevice, and when the wall shear rate was increased to 1000 sec-1 for this crevice size, the 
average intensity decreased to <15.  
The greatest platelet deposition occurred on the type I collagen samples. The intensity 
images revealed that large thrombi formed along the entire entrance of the crevice, on the 
collagen coverslip. The least amount of deposition occurred on the MPC-Ti6Al4V samples with 
an average intensity <10. 
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Figure 22. Color maps depicting the average intensity of the platelet deposition within each crevice size, over time, 
at a perfusion rate of 125 uL/min and a wall shear rate of 400 sec-1. The direction of flow is down for the main 
channel, outside of the crevice.  
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Figure 23. Color maps depicting the average intensity of the platelet deposition within each crevice size, over time, 
at a perfusion rate of 310 uL/min and a wall shear rate of 1000 sec-1. The direction of flow is down for the main 
channel, outside of the crevice.  
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Figure 24. The direction of flow is down. Color maps depicting the average intensity of the platelet deposition on 
each material over time, at a perfusion rate of 125 uL/min and a wall shear rate of 400 sec-1. Crevice size of 90 ± 12 
µm. 
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Figure 25. The direction of flow is down. Color maps depicting the average intensity of the platelet deposition on 
each material over time, at a perfusion rate of 310 uL/min and a wall shear rate of 1000 sec-1. Crevice size of 90 ± 
12 µm. 
3.3.3 Representative real-time perfusion videos 
Representative accelerated videos of platelets depositing within the crevices for 
different materials and the two wall shear rates are available in the supplemental material 
of this report (Videos 3.1-3.7). At both wall shear rates, two flow regimes are visible 
within the crevice: the primary flow path that curves into the crevice from the main 
channel flow at the proximal corner and rejoins the main channel flow at the distal corner, 
and a secondary vortex that forms further within the crevice. The diameter of the vortex 
decreased in size with the decrease in crevice width. In the 53 µm and 90 µm crevices  
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(Videos 3.1 and 3.2), the platelets initially adhered to the distal corner, nearest the main 
channel, and grew upward toward the center of the crevice. As the thrombi grew and 
partially occluded the crevice, the vortex was disturbed and the flow within the crevice 
became more unstable.  When the wall shear rate was increased to 1000 sec-1, the stability of the 
thrombi decreased and more embolization events were observed (Video 3.3 and Video 3.4).  
Only a few embolization events were noted within the 137 µm crevice or on the MPC-Ti6Al4V 
at both wall shear rates (Video 3.5 and Video 3.6).  
3.4 DISCUSSION 
The fluid flow pathway within a blood-wetted medical device is an important determinant of the 
likelihood for thrombus development and subsequent embolization. According to Virchow’s 
triad, it is one of the three major factors that affect thrombosis along with surface and the status 
of the blood.[126] Therefore, it is important to consider blood flow patterns when designing 
cardiac devices and selecting blood contacting biomaterials. Several studies have used PIV to 
characterize fluid flow within irregular geometries, such as bifurcations, steps, and crevices, and 
in specific cardiovascular devices in order to identify regions that could potentially promote 
thrombus formation.[49, 57, 127-129]  Studies using this method have been able to ascertain 
potentially hazardous flow patterns (i.e. recirculation and stagnation). However, platelet-sized 
particles [57, 129] or red blood cells in platelet poor plasma [49, 127] are used in this technique 
as the tracing particles instead of biologically active platelets.  
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Many microfluidic devices have been designed to investigate the effect of the blood flow 
pathway on the development of thrombi. Unlike PIV, this technique utilizes active platelets to 
characterize how disturbed flow contributes to platelet adhesion and aggregation.[14, 31-33]  
The majority of these studies examine platelet deposition onto collagen-coated or uncoated glass 
coverslips after backward steps, sudden expansions, or stenosis.[50, 55, 130, 131]  
Few studies have examined how complex flow paths affect the adhesion or deposition of 
platelets onto a biomaterial.[72, 124] Goodman et al. [72] used an experimental flow cell 
consisting of polyethylene tubing with sudden constrictions. Heparinized human blood was 
perfused through ﬂow cells and thrombus growth was observed with video-microscopy. It was 
found that there were three regions of substantial platelet deposition; at the point of contraction, 
at the point of expansion, and at the ﬂow reattachment point. Schaller et al. [124] developed a 
stagnation flow chamber to examine how flow stagnation and a continuum of wall shear rates 
affected platelet adhesion onto glass coverslips that were thinly coated with commercial 
polyurethanes or adsorbed von-Willebrand factor as their test materials. Although these 
techniques provide a way to examine real-time platelet deposition onto biomaterials, the flow 
conditions are not related to the defects or design attributes of many cardiovascular devices 
Previous PIV studies of sudden expansions and constrictions revealed that the highest 
concentration of platelet sized partials was in the coroners, where there were regions of 
recirculating flow.[49, 72] These results would suggest that the greatest platelet deposition would 
have been located towards the back of the crevices where the secondary vortices formed. 
However, it was found here that the regions of greatest deposition occurred on the distal corners 
of the crevices toward the main channel. This may have occurred because the distal corner is the 
first area the platelets impact, and the secondary flow vortex pattern increases the cumulative 
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time that platelets can interact with this area. Once platelets adhere and activate within this 
region, they release their granules and initiate biochemical pathways that result in a local flux of 
platelet agonists, creating a positive feedback loop that promotes further deposition. Ha et el. 
[130] and Taylor et al. [132] found that platelet deposition onto collagen initially occurred on the
edge of a sudden expansion but then progressed into the corner. The crevices are similar to a 
sudden expansion followed quickly by a sudden constriction. This creates two distinct flow 
paths: the secondary flow vortex pattern and the primary flow path that curves into the crevice 
from the main channel flow at the proximal corner and then rejoins the main channel flow at the 
distal corner. This primary flow path would transport platelets away from the crevice after some 
potential interaction with the distal corner, and may be why the thrombus does not grow into the 
bottom of the crevice. 
Cardiovascular device manufactures generally try to minimize the size of discontinuities 
and crevices within their devices to intuitively reduce their potential to promote thrombus 
formation. However, in the size range examined, it was found that the largest crevice was the 
least thrombogenic. The real-time videos show that platelets tended to remain trapped in the 
vortices of the 53 and 90 µm crevices for an extended period of time when compared to the 137 
µm crevice. Therefore platelets in the 137 µm crevice were exposed to the disturbed flow 
patterns, artificial material, and biochemical agonist for a shorter period of time when compared 
to the other crevice sizes, making it less likely they would activate and adhere.  
Although this was an acute study, the real-time visualization method employed provides 
the ability to investigate the initiation and potentiation of thrombus deposition generated by 
irregular geometries with opaque materials. For example, the color maps and surface coverage 
analysis suggest that when one increases the shear rate to 1000 sec-1, platelet adhesion within the 
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53 µm crevice decreases. However, the videos show that the thrombi that form in the crevice are 
not stable. In Video 3.5 the thrombus that formed in the 53 µm crevice rotates with the 
secondary vortex. Often times this unstable thrombus would embolize, an effect not perceivable 
with endpoint analysis. This method also provides a way to investigate how the growth of 
thrombi affects the flow pattern within the crevice. As the deposition increases within the 53 µm 
and 90 µm crevices the flow becomes erratic, altering the shape of the secondary vortex. 
Several mathematical and computer models have been developed to try to predict platelet 
deposition and thrombus formation with simple flow paths.[72, 133] Some researchers have even 
incorporated flow over a step as part of their modeling.[133] However, the interpretation of these 
models is limited by the lack of experimental data characterizing the effects of steps and 
crevices, or the effect of common clinical biomaterials on thrombus formation. A robust 
predictive model of device thrombosis would reduce the time and resources spent in empirically 
seeking to design more blood-biocompatible cardiovascular devices. The methodology employed 
in this study and the type of data generated provides a means for the refinement and fitting of 
models that seek to simulate the thrombotic deposition process in blood-wetted devices. 
3.5 LIMITATIONS 
Some limitations of the current report are worth noting. Aside from the aforementioned acute 
nature of the blood perfusion experiments, the results are also limited by the 2D nature of the 
flow pathway. The biomaterial only comprised the bottom (imaged) surface of the flow chamber. 
The other surfaces of the channel were albumin-passivated PDMS, in an effort to minimize any 
effects from platelet deposition onto non-test material. Etching the flow path directly into a 
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Ti6Al4V surface may be possible to create only one non-test surface, however etch techniques 
that were evaluated (data not shown) were not able to achieve the precision or tolerance 
necessary to make a crevice with smooth, well defined walls. Further, the use of a PDMS 
channel allowed multiple materials to be tested with a consistently shaped geometry.  Another 
limitation was that only three crevice sizes were investigated. Limitations on the size range 
evaluated were the tolerance of the photo-etching technique employed and the field of view 
associated with the optical system. A rectangular geometry was chosen to represent an idealized 
crevice because the fluid flow within it has been well-characterized and this geometry is readily 
amenable to computational modeling.[134] There was some slight geometric distortions in the 
crevice shape due to the clamping mechanism used to seal the chamber, causing the edges to be 
slightly rounded. Finally, this study used a dilute suspension of red blood cells (25% hematocrit). 
Although this is lower than the average hematocrit for healthy individuals, it is not atypical for 
patients implanted with VADs.[118]  
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3.6 CONCLUSIONS 
The employed method provides a viable means for quantifying the effect of common geometric 
irregularities found in cardiovascular devices on platelet deposition. Interestingly, the least 
amount of deposition occurred in the largest crevice size. While the most deposition occurred in 
the 90 µm and 53 µm crevices at the lower wall shear rate. This suggests that the crevice size 
might be tailored, depending on the flow condition, to reduce the risk of thromboembolic events. 
These data could be used to improve the accuracy of a predictive model of thrombotic deposition 
in VADs to help determine the tolerable limits of these features.  These limits could then be 
incorporated in to the design of blood-wetted, implantable cardiovascular devices to improve 
their hemocompatibility.  
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4.0  CHARACTERIZING THE EFFECT OF SUB-THRESHOLD 
CONCENTRATIONS OF ADP ON PLATELET DEPOSITION ONTO CLINICALLY 
RELEVANT OPAQUE MATERIALS 
4.1 INTRODUCTON 
Heart failure patients often have abnormal coagulation that increases their risk of stroke and 
thrombotic events prior to VAD implantation. This hypercoagulable state may be caused by 
many factors. One factor is that heart failure patients often have elevated levels of biochemical 
agonists, such as thrombin, thromboxane, and adenosine diphosphate (ADP) that are known to 
promote thrombus formation.[58-60] Biochemical agonists can be categorized as either weak or 
strong depending on how strongly they promote platelet aggregation.[7] Although ADP is 
considered a weak agonist it plays an important role in thrombus formation. When a platelet is 
activated it releases dense granules, which contain a high concentration of ADP. This creates a 
positive feedback loop, promoting further platelet activation and aggregation. ADP induces an 
influx of extracellular Ca++, an important co-factor for platelet activation.[8] ADP has also been 
shown to work synergistically with other agonists to promote platelet aggregation.[7-9] ADP-
induced platelet aggregation is such a significant clinical concern that an anti-platelet medication 
has been developed to target the interaction between platelets and ADP. Clopidogrel (Plavix) 
reduces platelet activation through inhibiting the P2Y12 (ADP) receptor.[58] 
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 Platelet aggregometry data show that platelets can either be reversibly aggregated or 
irreversibly aggregated depending on the concentration of biochemical agonist added to the 
sample. For ADP, platelets are reversibly aggregated when exposed to an ADP concentration of 
less than 1.5 µM.[135-137]  However, a sub-threshold concentration of agonist may interact with 
other factors, such as shear stress and blood contact with artificial surfaces, to irreversibly 
aggregate platelets and cause thrombosis in VADs.  Understanding the functional relationship 
between shear stress, biochemical agonists, and artificial surfaces would be a useful tool in 
assessing the hemocompatibility of blood-wetted devices. The aim of this report is to investigate 
the effect of sub-threshold concentrations of ADP in conjunction with flow on platelet deposition 
onto clinically relevant opaque materials.  
4.2 MATERIALS AND METHODS 
4.2.1 Blood analog preparation  
Fresh whole blood was collected after informed consent from 12 healthy donors (8 male, 4 
female), who had refrained from taking any platelet altering medications 14 days prior to 
collection, with a mean age of 28 ± 5 years in accordance with Institutional Review Board 
guidelines. Platelet rich plasma (PRP) was collected by centrifuging heparinized blood (collected 
into 10 mL Vacutainer tubes, (158 USP lithium heparin, PD biosciences, Franklin Lakes, NJ, 
USA) at 250xg for 15 min. Platelets were fluorescently labeled by the addition of quinacrine 
dihydrochloride (0.5 μM final concentration, Sigma-Aldrich, St. Louis, MO, USA) to the PRP.  
Packed RBCs (type O-, Valley Biomedical Products & Services, Inc., Winchester, VA, USA) 
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were utilized to create RBC ghosts through the protocol established in section 2.2.2 of this 
report.[125] The blood analog used as the perfusate was made by mixing the fluorescently 
labeled PRP with the RBC ghosts to produce a final hematocrit of 25% and a final platelet 
concentration of 2.6 ± 0.43 × 108 per mL. 
4.2.2 Parallel plate flow chamber and membrane based agonist delivery system  
A parallel plate flow chamber that was described in Chapter 2.2.4 was modified for this 
study.[125] Briefly, the chamber consisted of a clear acrylic top plate with angled nylon inflow 
and outflow barbed connectors.  A titanium alloy sample (Ti6Al4V; LaunchPoint Technologies 
Inc., Goleta, CA, USA) or zirconia toughened alumina (ZTA) acted as the bottom plate of the 
chamber. Ti6Al4V was selected for study because it is employed by several current and 
experimental VADs for blood-contacting surfaces.[46] ZTA was chosen because previous 
studies have shown it to be significantly less thrombogenic than Ti6Al4V.[125] A simple 
clamping mechanism held the plates together, with a silicone gasket outlining the channel width 
and length (5 x 8 mm). Aluminum shim stock was placed between the plates to provide a 
precisely defined channel height of 0.076 mm. 
A membrane based agonist delivery system was designed to evenly introduce specific 
concentrations of adenosine diphosphate (ADP) into the blood analog over time (Figure 26 and 
Video 4.1). A thin walled, expanded polytetrafluoroethylene tubular membrane (Aeos ePTFE 
Extruded Sub-Lite-Wall®, inner diameter 0.91 ± 0.05 mm, wall thickness 0.01 ± 0.03 mm, Zeus 
Industrial Products, Inc., Orangeburg, SC, USA) was inserted through the polyvinyl chloride 
tubing (PVC; Saint-Gobain™ Vincon™ Flexible PVC Tubing, inner diameter 3.20 mm, wall 
thickness 6.40 mm, Fisher Scientific, Pittsburgh, PA, USA), directly before the barbed inlet of 
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the parallel plate chamber, using a 21 G needle (BD™ General Use and Precision Glide 
Hypodermic Needles, Fisher Scientific, Pittsburgh, PA, USA). A 1 µm pore size was chosen 
because it allows the agonist to be perfused into the blood analog while preventing the blood 
cells from entering the membrane. The membrane is secured to the needle using miniature heat-
shrink tubing (McMaster-Carr, Aurora, OH, USA) and the holes, made by the needle, in the PVC 
were sealed by non-toxic sealant (ECO-BOND Pet Safe, Eco-Bond Adhesives, LLC, Pewaukee, 
WI, USA).  
 
 
Figure 26. Membrane based biochemical agonist delivery system. A) Photo of the membrane based biochemical 
agonist delivery system. B) Schematic of the agonist delivery system. B.1) Side view of the system schematic. B.2) 
Front view of the system schematic. 
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4.2.3 Blood analog and agonist perfusion 
All non-test surfaces were passivated by incubation with 1% bovine serum albumin (BSA, 
microbiological grade powder; MP Biomedicals, LLC, Solon, OH, USA) in PBS for 20 min prior 
to perfusion. The whole blood analog was collected into a 20 mL polystyrene syringe (BD 
Biosciences) and pushed through the parallel plate flow chamber by syringe pump (Harvard 
Apparatus, Holliston, Massachusetts, USA) for 10 min at flow rates of 0.117 and 0.289 mL/min 
(wall shear rates of 400 sec-1 and 1000 sec-1 respectively at the center of the channel). 0, 115, or  
-230 µM of ADP (adenosine 5'-diphosphate, BD Biosciences) in PBS was collected into a 20 mL 
polystyrene syringe (BD Biosciences) and pushed through a syringe pump (Harvard Apparatus, 
Holliston, Massachusetts, USA) simultaneously with the blood analog. Depending on the wall 
shear rate of the blood analog, the ADP solution was either perfused at a blood flow rate of 5 or 
12.5 µL/min (400 and 1000 sec-1 respectively) so that the final concentration of ADP would be 
0, 5, or 10 nM/min at the site of the membrane. The blood analog was forced to flow around the 
membrane to promote mixing and even distribution of the agonist. 
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4.2.4 Image acquisition 
Platelet deposition was visualized within the crevices, in real time, using an inverted 
epifluorescence microscope (Olympus IX FLA, Olympus Corporation, Shinjuku, Tokyo, Japan) 
with a 40x super long working distance objective (PlanFL, phase contrast, working distance 6.5 
mm - 8.3 mm, numerical aperture 0.55; Olympus Corporation) and a 103W HBO short arc 
mercury lamp light source (OSRAM GmbH, Munich, Germany). Images were acquired every 
0.4 sec beginning at one min after the start of perfusion using a CCD camera (PCO-TECH Inc., 
Romulus, Michigan, USA).  
4.2.5 Fluorescent image analysis 
The percent of the surface covered by deposited platelets was computed through the protocols 
established in section 2.2.5 of this report protocols.[125] These images were also analyzed to 
determine the average area of the individual thrombi adhered to the surfaces over time. 
4.2.6 Statistical analysis 
All data are presented as mean ± standard error of the mean. Data were analyzed by two-way, 
repeated measures ANOVA with specific post- hoc testing using the Bonferroni correction. 
SPSS v23 (IBM Corp, Armonk, NY) was used for all statistical analyses. 
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4.3 RESULTS 
4.3.1 Acute platelet deposition 
The fluorescent images were analyzed to determine the percent of the blood contacting surface 
covered by adherent platelets over time (Figure 27). At a wall shear rate of 400 sec-1 (Figure 
27A), the addition of 10 nM of ADP caused a significant increase in platelet deposition onto 
Ti6Al4V (Ti6Al4V: 10 nM) with 35.5 ± 2.1% of the surface covered after 10 min of perfusion 
(N=6, P < 0.01). However, at the same ADP concentration, ZTA had the least amount of platelet 
deposition with a maximum platelet surface coverage of 10.1 ± 1.2% (ZTA: 10 nM, N=5, p < 
0.01). The addition of 5 nM of ADP did not significantly increase platelet deposition on 
Ti6Al4V (Ti6Al4V: 5nM) compared to the control (Ti6Al4V: 0 nM) with 9.9 ± 1.1% of the 
surface covered by platelets after 10 min of perfusion ( N=5, P < 0.01).  
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Figure 27. Percent of the test surface covered by deposited platelets. A) Wall shear rate 400 sec-1. B) Wall shear 
rate 1000 sec-1. 
 
At a wall shear rate of 1000 sec-1 (Figure 27B) the Ti6Al4V: 5 nM and Ti6Al4V: 10 nM 
samples had significantly increased platelet deposition when compared to the control with 39.0 ± 
4.6%, 37.1± 4.3% and 20.4 ± 2.9% of the surface covered after 10 min of perfusion respectively 
(N=6, P < 0.1). There is no significant difference in the platelet deposition between the Ti6Al4V: 
5 nM and Ti6Al4V: 10 nM samples. After 10 min of perfusion, the platelet deposition on ZTA: 
10 nM was significantly less than the Ti6Al4V: 5 nM and Ti16Al4V: 10 nM samples at 20.4 ± 
2.5 (N=5, P < 0.01). However, the thrombogenicity of ZTA was essentially equivalent to that of 
the control Ti6Al4V sample. When examining the effect of wall shear rate (Figure 28), platelet 
deposition increased with the increase in shear rate for the Ti6Al4V: 5 nM and ZTA: 10 nM 
samples (P < 0.01, Figure 28B and 28D respectively). At both shear rates the platelet surface 
coverage significantly increased with time on all of the samples (P < 0.01). 
 
83 
Figure 28. Effect of wall shear rate on the percent of the test surface covered by deposited platelets. A) Ti6Al4V: 10 
nM ADP. B) Ti6Al4V: 5 nM ADP. C) Ti6Al4V: 0 nM ADP. D) ZTA: 10 nM ADP 
The average area of individual thrombi adhered to the surface was also examined using 
the fluorescent images (Figure 29). At a wall shear rate of 400 sec-1 (Figure 29A), there was no 
significant difference in thrombi size between the Ti6Al4V: 5 nM, Ti6Al4V:  0 nM, and ZTA: 
10 nM samples with an average individual thrombi area of 192 ± 20, 146 ± 7, and 152 ± 17 µm2 
respectively. The largest thrombi were adhered to Ti6Al4V: 10 nM samples with an average area 
of 328 ± 51 µm2 at the end of the perfusion experiment (P = 0.01).  
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Figure 29. Average area of individual thrombi over time. A) Wall shear rate 400 sec-1. B) Wall 
shear rate 1000 sec-1 
 
At a shear rate of 1000 sec-1 (Figure 29B) the largest thrombi were found on the 
Ti6Al4V: 5 nM and Ti6Al4V: 10 nM samples with an average individual thrombi area of 639 ± 
220 and 608 ± 151 µm2 respectively. The thrombi generated on these samples were significantly 
larger than the Ti6Al4V: 0 nM and ZTA: 10 nM samples (P = 0.03). The area of the thrombi on 
ZTA: 10 nM was not significantly different from the titanium control with an average individual 
thrombi area of 152 ± 17 and 186 ± 10 µm2 after 10 min of perfusion. When comparing the 
effect of wall shear rate the average individual area of the adherent thrombi increased with the 
increase in shear rate for the Ti6Al4V samples (Figure 30B). However, the average area of 
thrombi on the other samples is not significantly affected by shear rate (Figure 30). 
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Figure 30. Effect of wall shear rate on average area of individual thrombi over time. A) Ti6Al4V: 10 nM ADP. B) 
Ti6Al4V: 5 nM ADP. C) Ti6Al4V: 0 nM ADP. D) ZTA: 10 nM ADP. 
4.3.2 Representative real-time perfusion videos 
Representative real-time perfusion videos of platelet deposition at each experimental flow 
condition are available in the supplemental material of this report (Videos 4.1-4.8). At the 
lower wall shear rate the videos of the Ti6Al4V: 5 nm, Ti6Al4V: 0 nM, and ZTA: 10 nM looked 
similar with the thrombi growing in elliptical patterns, with the long axis aligned in the 
direction of flow (Videos 4.1-4.3). However, the ZTA: 10 nM video shows that few 
platelets adhere to the surface when compared to the other videos. Platelets rapidly adhered 
86 
to the Ti6Al4V:10nM surface,  at both wall shear rates, and Ti6Al4V: 5nM surface, at the higher 
shear rate. The thrombi form in a more spherical pattern on these samples (Video 4.4, 
4.5 and 4.8). Embolization of thrombi with a diameter of greater than 20 µm was observed 
sporadically with the Ti6Al4V: 10 nM samples, at both shear rates, and Ti6Al4V: 5 nM samples 
the wall shear rate of 1000 sec-1. An example of these emboli is shown in Figure 31 and Figure 
32. This sporadic embolization may be why the standard error for these samples is more than 2 
fold greater than the other surfaces.   Examination of the length of the flow path following 
perfusion indicated that platelets reacted uniformly with the test materials and were not 
diffusion-limited by the rapid depletion of platelets onto the surface at the inlet of the chamber.
[77] 
Figure 31. Representative fluorescent images of embolization at a wall shear rate of 400 sec-1.  Embolization was 
only seen when 10 nM of ADP was added to the blood analog perfusing over the Ti6Al4V surface. Scale bar = 40 
µm 
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Figure 32. Representative fluorescent images of embolization at a wall shear rate of 1000 sec-1.  Embolization was 
seen when 5 nM or 10 nM of ADP was added to the blood analog perfusing over the Ti6Al4V surface. Scale bar = 
40 µm. 
4.4 DISCUSSION 
The study described in this report is one of the few studies that examines all three factors that 
contribute to thrombus formation in blood-wetted devices as defined by Virchow’s triad 
(material reactivity, blood composition, and blood flow).  Specifically, this report describes a 
method for investigating the effect of ADP induced platelet aggregation prior to contact with 
clinically relevant VADs. VAD patients often experience several hematological events, such as 
hemolysis, that increase the concentration of ADP within the blood that could lead to increased 
thrombus formation within the devices.[39] Studies have shown that ADP released during 
hemolysis can increase platelet aggregation and adhesion. Alkhamis et al. investigated the 
 88 
release of ADP, from whole blood, when it is subjected to a shear stress. The investigators 
utilized a cone and plate viscometer to produce laminar shear stress (0.7 uM-5uM of ADP).[138, 
139] Numerical modeling studies have suggested that ADP released from already formed 
thrombi may contribute to platelet activation and downstream thrombi formation.[140-142] 
Although the experiments described in this report only utilize ADP to sensitize the platelets prior 
to material contact, it is still applicable to “pre-activation” of platelets with other agonist. Platelet 
activation may be initiated by a variety of agonists including, but not limited to, thrombin, 
serotonin, and thromboxane.[136, 143-145] 
Furthermore, heart failure patients tend to be associated with a hypercoagulable state. 
Reduced myocardial contractility leads to low cardiac output and abnormal blood flow that can 
initiate coagulation. Patients with heart failure often have dysfunctional endothelium, which can 
no longer act as an anticoagulant barrier. Furthermore, VAD patients have elevated plasma levels 
of clotting factors, adhesion molecules, and growth factors, such as von Willebrand factor (vWf), 
P-selectin, and vascular endothelial growth factor.[58] Infection, which occurs at a rate of 9.96 
events/ 100 patient months in the first 12 months post-implant, can elevate plasma levels of 
inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1 (IL-1),that are 
known to activate platelets.[1, 58] 
 Several studies have utilized platelet aggregometry to analyze the effect of biochemical 
agonists, such as ADP, on platelet aggregation.[135-137, 146] There are two main types of 
platelet aggregometry: impedance and light transmission. For impedance aggregometry, an 
agonist is added to an aliquot of whole blood and two electrodes are inserted into the sample. 
Platelet aggregation is measured by the increase in electrical impedances generated by platelets 
adhering to and aggregating on the electrodes. Light transmission aggregometry uses a 
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photometer to measure the light transmitted through a sample of PRP after the addition of a 
biochemical agonist. The light transmission through the sample increases as the sample 
aggregates due to the precipitation of platelet aggregates. In both methods, the blood is 
continuously mixed through stirring or shaking of the sample.[147] Aggregometry is a useful 
method for examining platelet aggregation. However, the blood is not exposed to flow conditions 
typically found in cardiac devices. Furthermore, this assay does not examine the effect of 
biomaterials on aggregation. 
 Few studies have examined the effect of biochemical agonist on platelet aggregation, 
under flow. Bell et al. examined ADP-induced platelet aggregation under flow in polyethylene 
tubes.  They measured the quantity and size of platelet aggregates formed when 0.2 or 1 µM of 
ADP was added to the blood. They found that an increase in ADP concentration caused an 
increase in the quantity and size of ADP.[148] A major limitation to their study is that the 
agonist was mixed rapidly with the blood by a magnetic stir prior to being perfused through the 
tubing. The flow conditions caused by the mixing, along with platelets interacting with the 
artificial surface of the stir bar, may have contributed to the formation of platelet aggregates. 
Also, they only investigated platelet aggregation and did not examine platelet adhesion to the 
surface of the tubing.[148] 
Neeves et al. developed a membrane-based device that allowed for the introduction of 
ADP into flowing blood at three defined fluxes. The device consisted of a fibrinogen coated 
polycarbonate membrane that was reversibly sealed between two parallel plate flow chambers. 
One chamber contained the flowing blood and the other contained the agonist.  Utilizing 
fluorescent microscopy, they examined the effect of introducing ADP.[149] Importantly, the 
study performed by Neeves et al. did not evaluate platelet deposition onto a biomaterial because 
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the membrane was coated in fibrinogen. This method could be used to examine platelet 
deposition onto a biomaterial. However, due the design of the device, platelet adhesion could 
only be examined on the membrane surface, limiting the utility of the technique.   Specifically, 
the method could not be used to examine the metallic surface currently utilized in most 
implantable continuous flow VADs, Additionally, Neeves et al. only examined platelet 
aggregation at one wall shear rate (250 sec-1). Expectantly, they found that the increase in ADP 
flux resulted in an increase in platelet aggregation.[149] 
 The most significant result of these studies was the discovery of the synergistic 
amplification of biochemical agonists by shear. This is illustrated in Figure 27. This figure 
shows that at a wall shear rate 400 sec-1 the addition of 5 nM ADP did not significantly increase 
platelet deposition. However increasing the wall shear rate to 1000 sec-1 resulted in nearly a 2.5 
fold increase in deposition on the titanium surface. Furthermore, the real-time fluorescent videos 
showed that this same dilute quantity of ADP increased the frequency of embolization, as well as 
the size of the emboli. This is particularly interesting because numerical modeling studies have 
suggested that local concentrations of ADP downstream of where the agonist was introduced 
would be lower at a higher wall shear rate.[140-142] This would suggest that platelets perfused 
at 400 sec-1 would be exposed to a higher local concentration of ADP at the surface of the 
titanium compared to the higher shear rate and, therefore, would be more likely to aggregate and 
adhere to the surface.  
One explanation for this discontinuity may be that the local ADP concentration at the 
surface of the titanium is great enough when combined with the reactivity of the surface to cause 
platelet aggregation and adhesion at both wall shear rates.  Therefore, the increase in platelet 
deposition at the higher shear rate may be due to the increased transportation of platelets to the 
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Ti6Al4V surface. Also, 5 nM is 300 times lower than the threshold value measured by 
aggregometry.[135-137] Thus, any platelets aggregated initially by the addition of this 
concentration are likely to be reversibly aggregated.  At a wall shear rate of 400 sec-1, the 
platelets may return to their resting state prior to contact with the titanium. While at 1000 sec-1, 
the platelets may not have time to return to resting state before they are further activated by 
contact with the artificial surface.  
The addition of 10 nM of ADP did not cause any embolization. Furthermore, even at 
1000 sec-1 platelet deposition on the ZTA: 10 nM sample was not significantly different than the 
control (Ti6Al4V: 0 nM). This suggests that this synergistic effect of shear and agonist can be 
negated though the utilization of a less thrombogenic material. 
 Several mathematical and computer models have been developed to try to predict platelet 
deposition and thrombus formation with simple flow paths.[72, 78, 133] Some models, such as 
the ones described in Sorensen et al. and Goodman et al. have incorporated biochemical agonists 
into their analysis.[72, 78] However, these modes require the agonist to be at critical level to 
affect platelet activation and do not consider the combined effect of material contact and agonist 
exposure. The study described in this report illustrated that a sub-critical level of ADP, in 
conjunction with flow and material contact, can cause a significant increase in platelet 
deposition. The data generated from this analysis could be used to improve the utility and 
accuracy to these and other predictive models of thrombosis. 
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4.5 LIMTATIONS 
 A major limitation to this report is the acute nature of the study. The test materials are only 
exposed to the blood for 10 min. However, the real-time visualization method employed 
provides the ability to investigate thrombus formation and embolization caused by the addition 
of a sub-threshold agonist.  Another limitation is the emboli witnessed during this study are not 
hazardous due to their small size. However, these emboli could continue to grow downstream to 
a dangerous size. Wilhelm et al. utilized transcranial Doppler ultrasound to measure 
microembolic signals in VAD patients before, during, and after implantation. They also analyzed 
the patients’ coagulation state during this time. They found that patients who experienced 
microembolic showering had increased levels of prothrombin fragment F1.2. These data 
suggesting that microembolic showering is an indicator of increased coagulation activity that 
could result in a detrimental thromboembolic event.  
4.6 CONCLUSIONS 
The employed method provides a viable means for qualifying the functional effect of 
biochemical agonist, blood flow, and biomaterials on platelet deposition. This report found that 
the addition of a sub-threshold level of ADP resulted in a 2.5 fold increase in increase thrombus 
formation on Ti6Al4V. Furthermore, increasing the wall shear rate from 400 to 1000 sec-1 
significantly increased the effect of adding 5 nM of ADP. This indicates a synergistic 
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amplification of biochemical agonists by shear. It was also found that the thrombogenisity of the 
system could be significantly reduced by replacing Ti6Al4V with a ZTA. This suggests that 
utilizing ZTA as the blood contacting surface of VADs may help to improve the overall 
hemocompatibility of the device. Finally, the data generated could be utilized to validate and 
calibrate predictive models of device thrombosis.  
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5.0 CONTINUED RESEARCH AND FUTURE DIRECTIONS 
The studies presented in the previous section add to the scientific knowledge of thrombosis 
development in blood-wetted devices. The techniques described in these studies enable 
additional research to be performed in this area that will continue to advance the field. The 
following research opportunities outside of the objectives of this dissertation are possible due to 
the results of the work contained in this report. 
5.1 SYNERGISTIC EFFECT OF BIOCHEMICAL AGONIST ON PLATELET 
DEPOSITION ONTO CLINICALY RELEVENTS MATERIALS 
The results generated from the study described in Chapter 4.0 of this report show that there is a 
synergistic effect between ADP, material contact, and shear. Aggregometry studies have also 
shown that sub-threshold levels of ADP work synergistically with other agonists and proteins to 
promote platelet aggregation.[135, 136, 150]  However, few studies have investigated the effect 
of multiple agonists, as sub-threshold concentrations, on platelet adhesion onto biochemical 
agonist, under flow. The biochemical agonist delivery system described in chapter 4.2.2 could be 
modified to infuse multiple agonists simultaneously and used to study wider variety of 
combinations of agonists, shear, and surface chemistry. Periodic collection of the effluent and 
subsequent analysis with flow cytometry may aid in the mapping of the emboli composition. As 
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described previously, Bell et al examined ADP-induced platelet aggregation under flow in 
polyethylene tubes. They employed an electronic partial counter to quantify the number and size 
of single platelets and aggregates.[148] This technique could be incorporated into this study to 
provide further information on the dynamics of platelet embolization. 
  As discussed in section 1.3.3 the different anticoagulant and anti- platelet medications 
inhibit platelet aggregation and thrombus formation through a variety of different pathways.[61-
69]  Therefore, the technique described in section 4.2 could also be employed to investigate how 
commonly utilized anticoagulation and anti-platelet medications affect agonists-induced 
thrombus formation. The data generated from the proposed study could be used to incorporate 
the effect of anticoagulation therapies into a model of device thrombosis, increasing its utility. 
5.2 CHARACTERIZING THE EFFECT OF GEOMETRIC IRREGULARITES ON 
PLATELET DEPOSTION ONTO CLINICALY RELEVENT SURFACES 
5.2.1 Investigating the effect of crevice size and geometry 
As discussed in Chapter 3.0, geometric irregularities within the flow path of continuous flow 
VADs serve as a nidus for thrombus formation.[49]  A rectangular crevice was chosen because 
the flow patterns generated within it is well characterized and this geometry is readily amenable 
to computational modeling.[134] However, the majority of these features are the unintended 
consequence of merging multiple components. The resulting crevices are probably a variety of 
irregular geometries. The study described in Chapter 3.0 could be expanded to include numerous 
geometries (i.e. triangular or semicircular crevices). Several of the studies that have examined 
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the effect of steps on platelet deposition incorporated sharp corners into their features.[50, 55, 
130, 131] Rounding the corners of these regions produce a less rapid change of the contours of 
the flow path. This should reduce the erratic flow patterns generated by this change and may 
reduce thrombogenicity of that feature. The effect of the slope of the corner can also be 
investigated in the proposed study. These suggested experiments could help determine 
particularly thrombogenic geometries. 
 The majority of VAD manufacturers try to limit the size of the steps and crevices within 
the blood flow path by precision polishing and machining. Intuitively, the sizes of the generated 
crevices would be on the micron scale (< 50 µm). Furthermore, if a non-fixed VAD impeller 
collided with the housing surface it would likely create a microscopic scratch.[123] A limitation 
to the study described in Chapter 3.0 was that the smallest crevice sized evaluated was around 50 
µm.  Limitations on the size range evaluated were the tolerance of the photo-etching technique 
employed and the field of view associated with the optical system. However, the development of 
new technologies such as 3D nano-printers may make such an analysis possible. Investigating < 
50 µm sized crevices will generate additional data that could be used to determine the tolerable 
limits of these geometric irregularities. 
5.2.2 Pulsatile flow 
As discussed in Chapter 1, continuous flow VADs have improved mechanical durability, are 
smaller and have decreased power requirements compared to pulsatile VADS.[10] However, 
continuous flow VADS significantly decreased the pulsatile flow in the vascular system. Studies 
have shown that some patients supported by continuous flow VADs have experienced adverse 
cardiac events, such as aortic insufficiency, right heart failure, and gastrointestinal bleeding, 
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which were not witnessed in patients supported by pulsatile VADs.[151-153]  Some research 
groups are attempting to develop a method to modulate the speed of continuous flow VADs to 
mimic pulsatile flow and potentially reduce these adverse effects.[151, 152].  
 Currently there is a debate among scientific members of the VAD community on the 
effect of pulsatility on thrombus formation in continuous flow VADs. Some  studies suggest that 
increasing the pulsatility of continuous flow VADs will allow  the aortic valve to frequently open 
and provide regular washing of the pump.[152] Yang et al. performed a high-speed visualization 
of the flow patterns within the HeartMate II at steady and pulsatile flow conditions. They found 
that pulsatile flow induced a periodic disturbance within the device that created flow patterns 
known to contribute to thrombus formation.[57] These findings are supported by a recent report 
noting an increase in pump thrombosis when operating the pump at a lower speed during the 
weening phase of a ventricular recovery study.[154] Incorporating pulsatile flow into the study 
described in Chapter 3.0 would provide a method for visualizing the effect of pulsatile flow on 
platelet deposition within a defined crevice. The proposed study could potentially determine if 
pulsatility improves washing within the crevice or contributes to the potentially hazardous flow 
patterns.  
5.3 COMPARATIVE ANALYSIS OF HUMAN, BOVINE AND OVINE BLOOD 
The use of animal models to evaluate the biocompatibility of cardiovascular devices is an 
essential part of device development and must be conducted to ensure safety before a clinical 
trial can begin. However, the coagulation systems vary between different species.[96, 155-157] 
Few studies have performed a comparative analysis of species specific platelet activation and 
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thrombus formation. Baker et al. and Johnson et al. developed flow cytometry assays to 
investigate platelet activation and aggregation using bovine and ovine blood respectively, 
however they did not investigate platelet adhesion.[96, 157]  
Palagalli et al. investigated species specific (buffalos, horses, pig, sheep, and human) 
platelet adhesion onto fibrinogen in vitro. They found that horse platelets were most likely to 
adhere to the fibrinogen, whereas sheep (ovine) platelets were unable to adhere to autologous 
fibrinogen unless activated with ADP.[156]  Goodman et al. compared how human, ovine, and 
porcine platelets adhered to biomaterials in vitro. The biomaterials investigated in that study 
were pyrolytic carbon mechanical heart valve leaflets, National Institutes of Health-reference 
polyethylene and silicone rubber, and FormvarTM. The study found that platelet responses were 
strongly dependent on biomaterial and species. For example, both human and porcine blood 
spread extensively on pyrolytic carbon, while human platelets spread extensively on 
polyethylene but porcine platelets did not.[155] Although these studies offer a comparative 
analysis of species specific platelet adhesion, both studies were performed under stagnant 
conditions. Furthermore, they did not utilize whole blood or PRP. Instead the platelets were 
isolated from the blood through centrifugation and filtering. This process could have affected 
platelet function before blood contact with the test surface. 
The method described in Chapter 2.0-3.0 could be utilized to perform comparative 
analysis of the effect of blood donor species on platelet deposition under flow. Therefore, using 
these techniques as a method for comparing different animal models would be a useful tool in 
selecting the appropriate model based on the blood contacting material and blood flow patterns. 
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5.4 IN VIVO VALIDATION OF IN VITRO VISUALIZATION AND ANALYSIS OF 
BIOMATERIAL-CENTERED THROMBUS FORMATION WITHIN A DEFINED 
CREVICE  
5.4.1 Visualization of platelet adhesion 
The in vitro method employed in Chapter 3 of this report provides a viable means for quantifying 
the effect of common geometric irregularities found in cardiovascular devices on platelet 
deposition. However, due to its acute nature the results would need to be validated in vivo to 
prove the clinical significance of the study. This in vivo analysis could be achieved through the 
modifications of the visualization technique described by Wagner et al. and Schaub et al. (Figure 
33).[8, 43] They developed a fiber optic remote microscope to visualize and quantify platelet 
deposition onto an opaque surface, in a continuous manner. They also modified a polycarbonate 
centrifugal blood pump to include septums at the top and bottom to allow the fiber optic camera 
to be inserted into the blood flow path so that platelet deposition could be visualized.[8, 43] A 
similar pump could be designed to introduce a crevice of defined dimensions into the blood flow 
path. This device could then be implanted into a bovine animal model using percutaneous inlet 
and outlet cannula so that the pump remains visible similar to that of the CentriMag (Thoratec 
Corp, Pleasanton, CA, USA) continuous flow VAD. The thrombus formation within a crevice 
could then be visualized by the fiber optic remote microscope and the results could be compared 
to the in vitro analysis. 
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Figure 33. Method for in vivo visualization. A) Fiber optic remote microscope. B) Modified a polycarbonate 
centrifugal blood pump. From Wagner et al.[8] 
5.4.2 Hematological analysis of test subject’s blood 
It is difficult to diagnosis pump thrombosis and it is usually characterized by a pattern of clinical 
symptoms, laboratory findings, echocardiograph data, and device settings.[65]   An increased 
serum lactate dehydrogenase (LDH) level, is often the associated with late stage pump 
thrombosis, however there are few markers for early stage pump thrombosis. Furthermore, most 
continuous flow VADs are composed of opaque materials, making it impossible to visually 
detect pump thrombosis.[65, 158, 159] In order to investigate potential markers for early pump 
thrombosis, periodic samples could be taken from the pump described in the previous section 
and analyzed for coagulation markers (i.e thrombin and LDH). Since thrombus formation might 
be visually monitored via the fiber optic microscope, specific samples could be taken at the 
initiation of thrombosis and when the thrombosis grows to a potential hazardous size. The data 
generated could potentially identify biological markers that are associated with early 
development of pump thrombosis. 
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6.0  FINAL CONCLUSIONS 
VADs have become an established treatment option for patients with advanced heart failure. The 
first generation of VADs were pulsatile, positive displacement pumps that were designed to 
mimic the biphasic flow of the native heart. They were utilized as a bridge to transplant for heart 
failure patients waiting for a donor organ.[19]  Due to their large size, first generation pumps 
could only be used in a limited patient population. Additionally, the durability of these devices 
was limited. In order to produce pulsatile flow, pumps were complex with multiple moving 
parts.[12, 19, 160, 161] The introduction of continuous flow blood pumps decreased the size and 
power requirements and increased the mechanical life of VADs. This allowed pump utilization in 
a broader patient population. However, these devices are still plagued by thrombosis. The 
incidence of thrombosis, bleeding, and neurologic dysfunction experienced by patients supported 
by continuous flow VADs continues to limit the cost-effectiveness and clinical acceptance of the 
technology.[1, 2, 11, 12] 
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The creation of a computational model to predict thrombosis would reduce the time and 
cost of designing and producing safe, effective blood-wetted devices. Such a model could be 
used to determine prothrombogenic areas of devices prior to implantation. While several 
mathematical models have been developed to predict platelet activation and adhesion, there is 
still no computational model that can predict thrombosis in an actual device with any 
mathematical certainty.[70-75] The data generated from the studies described in this report could 
be used to improve the accuracy and advance the utility of such a predictive model.  
The method described in Chapter 2.0 provides a method for side-by-side biomaterial 
analysis. This is a useful tool for the selection and design of materials for use as a blood 
contacting surface. The results from this study show a reduction in platelet deposition at elevated 
wall shear rate. This suggests that the blood biocompatibility of VADs might be improved by 
minimizing the areas of low shear blood contact. Furthermore, this technique revealed that MPC-
TI6AL4V and ZTA have improved thromboresistance when compared to Ti6Al4V and, thus, 
may be alternatives for consideration in future VAD designs.  
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The method employed in Chapter 3.0 provides a viable means for quantifying the effect 
of common geometric irregularities found in cardiovascular devices on platelet deposition. 
Interestingly, the least amount of deposition occurred in the largest crevice size. At the higher 
shear rate, the most deposition occurred in the 90 µm crevice (medium size crevice). This 
suggests that the crevice size might be tailored, depending on the flow condition, to reduce the 
risk of thromboembolic events. As described in the future directions section of this report, this 
study could be advanced to incorporate more clinically relevant crevice sizes and shapes, thus 
generating additional data that could be used to determine the tolerable limits of these geometric 
irregularities. The in vivo study described in the future directions section could be used to 
validate this in vitro study, thus improving its clinical significance. 
The method described in Chapter 2.0-3.0 could be utilized to perform comparative 
analysis of the effect of blood donor species on platelet deposition under clinically relevant flow 
conditions. Studies have shown that platelet adhesion is dependent on both species and 
material.[27] Therefore, using these techniques as a method for comparing different animal 
models would be a useful tool in selecting the appropriate model based on the blood contacting 
material and blood flow patterns. This is clinically relevant because an improved in vivo animal 
model would result in a more accurate assessment of the biocompatibility of a blood wetted 
device under investigation. Therefore, it would be less likely that an unexpected adverse advent 
would occur when the device is implanted in patients.  
According to Virchow’s triad, there are three factors that contribute to thrombosis in 
blood wetted devices: the composition of the blood, the blood flow, and biomaterial contact. [37, 
38] Although the triad was developed in 1856, the functional relationship of all three factors is 
not well characterized. The study described in Chapter 4 incorporated all aspects of the triad into 
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the analysis. It was found that shear and ADP work synergistically to increase platelet 
aggregation and deposition. This was indicated by the nearly 2.5 fold increase in platelet 
deposition with the addition of a sub-threshold level of ADP. It was also found that this 
synergistic effect could be negated though the utilization of a less thrombogenic material. 
Currently there is no accurate way of detecting the early stages of pump thrombosis. 
Furthermore, it is impossible to visually detect pump thrombosis in most continuous flow VADs 
because the pump housings are made of opaque materials.[7, 33, 34] In order to investigate 
potential markers for early pump thrombosis, periodic samples could be taken from the pump 
described in the future directions section of this report and analyzed for coagulation markers (i.e. 
thrombin and LDH). The thrombus formation could be visually monitored via the fiber optic 
microscope, therefore it could be known if a thrombus has formed in the pump at the time the 
sample is collected. The data generated could potentially identify biological markers that are 
associated with early development of pump thrombosis. 
Although there are still many aspects of pump thrombosis that are unknown, from the 
results of this report, I hypothesize that the blood biocompatibility of VADs can be improved by 
coating the Ti6Al4V surface with MPC. This would allow the manufacturers to continue to 
utilize the easily machined titanium alloy, while improving the blood compatibility of their 
device. Furthermore, future VADs might have fewer regions of potentially hazardous flow 
conditions by intentionally producing larger crevices in the areas where multiple materials are 
combined. Incorporating more favorable crevice geometries and sizes into the VAD design could 
improve the overall blood biocompatibility of the device. 
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APPENDIX A 
REPRESENTATIVE REAL-TIME PERFUSION VIDEOS 
As previously mentioned the, representative real-time perfusion videos of platelet deposition are 
available in the supplemental material of this report. Below are the descriptions that accompany 
those videos.
A.1 REAL TIME VISUALIZATION AND CHARACTERIZATION OF PLATELET 
DEPOSITION UNDER FLOW ONTO CLINICALLY RELEVANT OPAQUE 
SURFACES 
Video 2.1: Representative real-time perfusion video of platelets adhering to Ti6Al4V, at a wall 
shear rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 
μm. 
Video 2.2: Representative real-time perfusion video of platelets adhering to SiC, at a wall shear 
rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 μm. 
Video 2.3: Representative real-time perfusion video of platelets adhering to Al2O3, at a wall 
shear rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 
μm. 
Video 2.4: Representative real-time perfusion video of platelets adhering to YZTP, at a wall 
shear rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 
μm. 
Video 2.5: Representative real-time perfusion video of platelets adhering to ZTA, at a wall shear 
rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 μm. 
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Video 2.6: Representative real-time perfusion video of platelets adhering to MPC-TI6AL4V, at a 
wall shear rate of 400 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar 
= 20 μm. 
Video 2.7: Representative real-time perfusion video of platelets adhering to Ti6Al4V, at a wall 
shear rate of 1000 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 
20 μm. 
Video 2.8: Representative real-time perfusion video of platelets adhering to SiC, at a wall shear 
rate of 1000 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 20 μm. 
Video 2.9: Representative real-time perfusion video of platelets adhering to Al2O3, at a wall 
shear rate of 1000 sec-1.  The video speed was increased by a factor of 9. Flow is up. Scale bar = 
20 μm. 
Video 2.10: Representative real-time perfusion video of platelets adhering to YZTP, at a wall 
shear rate of 1000 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 
20 μm. 
Video 2.11: Representative real-time perfusion video of platelets adhering to ZTA, at a wall 
shear rate of 1000 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale bar = 
20 μm 
Video 12: Representative real-time perfusion video of platelets adhering to MPC-TI6AL4V, at a 
wall shear rate of 1000 sec-1. The video speed was increased by a factor of 9. Flow is up. Scale 
bar = 20 μm. 
A.2 VISUALIZATION AND ANALYSIS OF BIOMATERIAL-CENTERED 
THROMBUS FORMATION WITHIN A DEFINED CREVICE UNDER FLOW 
Video 3.1: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, within 
the 53 µm crevice, at a wall shear rate of 400 sec-1. The video speed was increased by a factor of 
18. Flow is down. Scale bar = 40 μm.
Video 3.2: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, within 
the 90 µm crevice, at a wall shear rate of 400 sec-1. The video speed was increased by a factor of 
18. Flow is down. Scale bar = 40 μm.
Video 3.3: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, within 
the 53 µm crevice, at a wall shear rate of 1000 sec-1. The video speed was increased by a factor 
of 18. Flow is down. Scale bar = 40 μm. 
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Video 3.4: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, within 
the 90 µm crevice, at a wall shear rate of 1000 sec-1. The video speed was increased by a factor 
of 18. Flow is down. Scale bar = 40 μm. 
Video 3.5: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, within 
the 137 µm crevice, at a wall shear rate of 1000 sec-1. The video speed was increased by a factor 
of 18. Flow is down. Scale bar = 40 μm. 
Video 3.6: Representative real-time perfusion video of platelets depositing onto MPC-Ti6Al4V, 
within the 90 µm crevice, at a wall shear rate of 1000 sec-1. The video speed was increased by a 
factor of 18. Flow is down. Scale bar = 40 μm. 
Video 3.7: Representative real-time perfusion video of platelets depositing onto Collagen, within 
the 90 µm crevice, at a wall shear rate of 1000 sec-1. The video speed was increased by a factor 
of 18. Flow is down. Scale bar = 40 μm. 
A.3 CHARACTERIZING THE EFFECT OF SUB-THRESHOLD 
CONCENTRATIONS OF ADP ON PLATELET DEPOSITION ONTO CLINICALLY 
RELEVANT OPAQUE MATERIALS 
Video 4.1: Example of diffusion though the membrane-based biochemical agonist delivery 
system. Colored water is pushed through the membrane into a PVC tube containing flowing, 
unaltered water.
Video 4.2: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 5 nM of ADP, at a wall shear rate of 400 sec-1. The video speed was increased by 
a factor of 18. Flow is down. Scale bar = 40 μm.
 
Video 4.3: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 0 nM of ADP, at a wall shear rate of 400 sec-1. The video speed was increased by 
a factor of 18. Flow is down. Scale bar = 40 μm. 
Video 4.4: Representative real-time perfusion video of platelets depositing onto ZTA, after the 
addition of 10 nM of AD, at a wall shear rate of 400 sec-1. The video speed was increased by a 
factor of 18. Flow is down. Scale bar = 40 μm. 
Video 4.5: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 10 nM of ADP, at a wall shear rate of 400 sec-1. The video speed was increased 
by a factor of 18. Flow is down. Scale bar = 40 μm. 
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Video 4.6: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 5 nM of ADP, at a wall shear rate of 1000 sec-1. The video speed was increased 
by a factor of 18. Flow is down. Scale bar = 40 μm. 
Video 4.7: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 0 nM of ADP, at a wall shear rate of 1000 sec-1. The video speed was increased 
by a factor of 18. Flow is down. Scale bar = 40 μm. 
Video 4.8: Representative real-time perfusion video of platelets depositing onto ZTA, after the 
addition of 10 nM of ADP, at a wall shear rate of 1000 sec-1. The video speed was increased by a 
factor of 18. Flow is down. Scale bar = 40 μm. 
Video 4.9: Representative real-time perfusion video of platelets depositing onto Ti6Al4V, after 
the addition of 10 nM, of ADP, at a wall shear rate of 1000 sec-1. The video speed was increased 
by a factor of 18. Flow is down. Scale bar = 40 μm. 
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